Muscle-invasive and Metastatic Bladder Cancer

7. DISEASE MANAGEMENT

7.1. Neoadjuvant therapy

7.1.1. Introduction

The standard treatment for patients with urothelial MIBC and MIBC with subtypes is RC. However, RC only provides 5-year survival in about 50% of patients [248-250]. To improve survival in patients with cN0M0 disease, cisplatin-based NAC has been used since the 1980s [248-252].

7.1.2. Role of cisplatin-based chemotherapy

There are theoretical advantages and disadvantages of administering chemotherapy before planned definitive surgery to patients with resectable muscle-invasive cN0M0 UC of the bladder:

• Chemotherapy is delivered at the earliest time-point, when the burden of micrometastatic disease is expected to be low.
• Potential reflection of in vivo chemosensitivity.
• Tolerability of chemotherapy and patient compliance are expected to be better pre-cystectomy.
• Patients may respond to NAC and have a favourable pathological response as determined mainly by achieving ypT0, ≤ ypT1, ypN0 and negative surgical margins. An analysis to identify the optimal definition of pathological response reported a significantly higher risk of recurrence in patients with ypTaN0 or ypT1N0 disease (with or without Tis) at RC and thus proposed that optimal pathological response after NAC be defined as attainment of ypT0N0/ypTisN0 at RC [253].
• Delayed cystectomy might compromise the outcome in patients not sensitive to chemotherapy [254-256]. A comparative survival analysis of patients treated with NAC and RC vs. RC alone based on data from the U.S. National Cancer Database showed that organ-confined disease (≤ pT2) after NAC was associated with decreased risk of death (HR: 0.85, 95% CI: 0.79–0.91) compared to RC alone, whereas > pT2 was associated with increased risk of death (HR: 1.46, 95% CI: 1.34–1.60) [257]. However, there are no prospective trials indicating that delayed surgery due to NAC has a negative impact on survival. In the phase III VESPER trial, comparing gemcitabine/cisplatin (GC) vs. high-dose-intensity methotrexate, vinblastine, doxorubicine and cisplatin (HD-MVAC) in the peri-operative setting, approximately 90% of patients proceeded to surgery (with median delay of 48 days for GC and 51 days for dd-MVAC) [258].
• Neoadjuvant chemotherapy does not seem to affect the outcome of surgical morbidity. In a recently reported large multicenter retrospective analysis, NAC did not lead to an increased risk of post-operative complications after RC [259]. In the combined Nordic trials (n = 620), NAC did not have a major adverse effect on the percentage of performable cystectomies. The cystectomy frequency was 86% in the experimental arm and 87% in the control arm with 71% of patients receiving all three chemotherapy cycles [260].
• Clinical staging using bimanual palpation, CT or MRI may result in over- and understaging and have a staging accuracy of only 70% [87]. Overtreatment is a possible negative consequence.
• Gender may have an impact on chemotherapeutic response and oncologic outcomes [261,262]. Female patients tend to have a better cancer-related response to NAC as compared to male patients.
• Neoadjuvant chemotherapy should only be used in patients eligible for cisplatin-combination chemotherapy; other combinations (or monotherapies) are inferior in metastatic BC and have not been fully tested in a neoadjuvant setting [263-270].

7.1.2.1. Summary of available data

Several phase III RCTs addressed the potential survival benefit of NAC administration [263-267,271-274]. The main differences in trial designs were the type of chemotherapy (i.e., single-agent cisplatin or combination chemotherapy) and the number of cycles provided. Patients had to be fit for cisplatin. Since these studies differed considerably for patient numbers, patient characteristics (e.g., clinical T-stages included) and the type of definitive treatment offered (cystectomy and/or RT), pooling of results was not possible.

Three meta-analyses were undertaken to establish if NAC prolongs survival [268-270]. In a meta-analysis including updated patient data from 11 randomised trials (n = 3,005), a significant survival benefit was shown in favour of NAC [270]. The most recent meta-analysis included four additional RCTs, and used the updated results from the Nordic I, Nordic II, and BA06 30894 trials including data from 427 new patients and updated information from 1,596 patients. The results of this analysis confirmed the previously published data and showed an 8% absolute improvement in survival at five years with a number needed-to-treat of 12.5 [275]. Only cisplatin-combination chemotherapy with at least one additional chemotherapeutic agent resulted in a meaningful therapeutic benefit [268,270]; the regimens tested were methotrexate, vinblastine, adriamycin (epirubicin) plus cisplatin (MVA(E)C), cisplatin, methotrexate plus vinblastine (CMV), cisplatin plus methotrexate (CM), cisplatin plus adriamycin and cisplatin plus 5-fluorouracil (5-FU) [276].

The updated analysis of a large phase III RCT [264] with a median follow-up of eight years confirmed previous results and provided additional findings:

• 16% reduction in mortality risk;
• improvement in 10-year survival from 30% to 36% with neoadjuvant CMV;
• benefit with regard to distant metastases;
• the addition of neoadjuvant CMV provided no benefit for locoregional control and locoregional DFS, independent of the definitive treatment.

More modern chemotherapeutic regimens such as GC have shown similar pT0/pT1 rates as methotrexate, vinblastine, adriamycin plus cisplatin in retrospective series and pooled data analyses [276-279]. Modified dd-MVAC was tested in two small single-arm phase II studies demonstrating high rates of pathologic complete remission [280,281]. Moreover, a large cross-sectional analysis showed higher rates of down-staging and pathological complete response for dd-MVAC [282].

In the GETUG/AFU V05 VESPER RCT of peri-operative chemotherapy, 500 patients were randomised to either 6 cycles of dd-MVAC once every 2 weeks vs. 4 cycles of GC once every 3 weeks prior to surgery (neoadjuvant group) or after surgery (adjuvant group) with a primary endpoint of progression-free survival (PFS) at 3 years. In 493 patients (437 neoadjuvant and 56 adjuvant), a similar pathologic response rate (ypT0N0) in patients treated with dd-MVAC 42% and GC 36% (p = 0.2) was seen. The < ypT2N0 rate was 63% and 50% in the dd-MVAC and GC patients, respectively. Organ-confined response (< ypT3N0) was observed more frequently in the dd-MVAC arm (77% vs. 63%, p = 0.001). For all patients in the trial, 3-year PFS was improved in the dd-MVAC arm, but the study did not meet its primary endpoint (3-year rate: 64% vs. 56%, HR: 0.77 [95% CI: 0.57–1.02], p = 0.066); nevertheless, the dd-MVAC arm was associated with a significantly longer time to progression (3-year rate: 69% vs. 58%, HR: 0.68 [95% CI: 0.50–0.93], p = 0.014). In the neoadjuvant group, PFS at 3 years was significantly higher in the dd-MVAC arm (66% vs. 56%, HR: 0.70 [95% CI: 0.51–0.96], p = 0.025). Dose- dense MVAC was associated with more severe asthenia and GI side effects than GC [258,283]. In a single-center retrospective analysis in patients with MIBC, neoadjuvant accelerated MVAC was safe and efficacious irrespective of age, provided that patients were fit and deemed suitable candidates for cisplatin [284]. Another dose- dense regimen using GC was reported in two small phase II trials [285,286]. While pathological response rates (< pT2) in the range of 45%–57% were achieved, one trial had to be closed prematurely due to high rates of severe vascular events [285]. This approach is therefore not recommended outside of clinical trials.

As an alternative to the standard dose of cisplatin-based NAC with 70 mg/m2 on day 1, split-dose modifications regimens are often used with 35 mg/m2 on days 1+8 or days 1+2. In a retrospective analysis the standard schedule was compared to a split-dose schedule in terms of complete and partial pathological response. A lower number of complete and partial response rates was seen in the split-dose group, but these results were not statistically significant [287].

Efforts aimed at improving the efficacy of NAC in MIBC are ongoing. In the double- blind, randomised, placebo-controlled, phase II NEOBLADE trial of neoadjuvant gemcitabine and cisplatin chemotherapy with nintedanib, a small molecule inhibitor that targets tyrosine kinases PDGFR, FGFR-1, and VEGFR-2, or placebo, in locally-advanced MIBC, the addition of nintedanib to chemotherapy was safe but did not improve the rate of pathological complete response [288].

There seem to be differences in the outcomes of patients treated with NAC for primary or secondary MIBC with retrospective data suggesting that patients with primary MIBC have better pathologic response rates to NAC in comparison to patients with secondary MIBC [289]. However, in the absence of prospective data, patients with secondary MIBC should be treated similarly to those presenting with primary MIBC [225].

It is unclear, if patients with non-UC histology will also benefit from NAC. A retrospective analysis demonstrated that patients with neuroendocrine tumours had improved OS and lower rates of non-organ-confined disease when receiving neoadjuvant cisplatinum/etoposide chemotherapy. In case of micropapillary differentiation, sarcomatoid differentiation and adenocarcinoma, lower rates of non-organ confined disease were found, but no statistically significant impact on OS. Patients with SCC did not benefit from NAC [290]. A 2019 systematic review showed benefit of NAC for patients with micropapillary-, plasmacytoid-, sarcomatoid-, and mixed variants but especially for patients with neuroendocrine tumours [66]. A U.S. National Cancer Database study evaluating potential associations between receipt of NAC, pathological downstaging and OS for patients with histological subtype MIBC demonstrated that NAC was associated with pathological downstaging for all MIBC histological subtypes (UC; sarcomatoid UC; micropapillary UC; SCC; neuroendocrine carcinoma; and adenocarcinoma), with improved OS for patients with UC, sarcomatoid variant UC and neuroendocrine carcinoma [291].

7.1.3. The role of imaging and predictive biomarkers (see also section 5.2)

Data from small imaging studies aiming to identify responders in patients treated with NAC suggest that response after two cycles of treatment is predictive of outcome. Although mpMRI has the advantage of better resolution of the bladder wall tissue planes as compared to CT, it is not ready yet for standard patient care. However, bladder mpMRI may be useful to inform on tumour stage after TURB and response to NAC [119]. So far PET/CT, MRI or DCE-MRI cannot accurately assess treatment response [292-295]. To identify progression during NAC, imaging is being used in many centres notwithstanding the lack of supporting evidence.

For responders to NAC, especially in those with a complete response (pT0 N0), treatment has a major positive impact on OS [296,297]. Therefore, reliable predictive markers to identify patients most likely to benefit from chemotherapy are needed. A study investigated how molecular subtypes impact pathological response and survival in patients receiving pre-operative cisplatin-based chemotherapy [298]. Patients with genomically unstable (GU) and urothelial-like (Uro) tumours had higher proportions of complete pathological response (16/31 [52%] and 17/54 [31%] vs. 5/24 (21%) for the basal/squamous (Ba/ Sq) subtype) following NAC and RC. Molecular subtype was independently associated with improved survival for patients with GU tumours (HR: 0.29, 95% CI: 0.11–0.79) and UroC tumours (HR: 0.37, 95% CI: 0.14–0.94) compared with Ba/Sq tumours, adjusting for clinical stage. Molecular tumour profiling might guide the use of NAC in the future but, as yet, this is not applicable in routine practice [299-301] (see Chapter 6 - Markers).

7.1.4. Role of neoadjuvant immunotherapy and chemo-immunotherapy

Inhibition of PD-1/PD-L1 checkpoint has demonstrated significant benefit in patients with unresectable and metastatic BC in the second-line setting and in platinum-ineligible PD-L1+ patients as first-line treatment using different agents. Checkpoint inhibitors are increasingly tested also in the neoadjuvant setting; either as monotherapy or in combination with chemotherapy or CTLA-4 checkpoint inhibition. Data from two phase II trials have been presented with encouraging results [241,242]. The results of PURE-01, a phase II trial using the PD-1 inhibitor pembrolizumab reported a complete pathological remission (pT0) in 42% and pathological response (< pT2) in 54% of patients, whereas in the single-arm phase II trial with atezolizumab a pathologic complete response rate of 31% was reported. In an update to the ABACUS trial using single-agent atezolizumab, two-year DFS and OS were 68% (95% CI: 58–76) and 77% (95% CI: 68–85), respectively with two-year DFS in patients achieving a pathological complete response of 85% (95% CI: 65–94) [302]. In a update of PURE-01, after a median follow-up of 39 months, 36-month EFS and OS were 74% (95% CI: 68-82) and 84% (95% CI: 78-90), respectively with RFS in patients achieving a complete pathologic response of 96% (95% CI: 89-100) [303]. The combination of anti-CTLA4 and anti-PD1 therapy has also been investigated in the neoadjuvant setting. In the NABUCCO study using pre-operative ipilimumab and nivolumab, the pathologic complete response was 46% with 58% having no remaining invasive disease (pT0N0/pTisN0/pTaN0) [304]. In a second study using pre-operative tremelimumab and durvalumab in cisplatin-ineligible patients, the pathological complete response was 37.5% and downstaging to pT1 or less was seen in 58% of patients who completed surgery [305].

Three studies have been published to date investigating the use of neoadjuvant chemo-immunotherapy in patients with MIBC. In a phase II study of gemcitabine plus split-dose cisplatin and pembrolizumab in patients with MIBC, 22 of 39 patients (56% [95% CI: 40–72]) achieved < pT2N0 and 14 of 39 (36% [95% CI: 21–53]) achieved pT0N0 [306]. In a second phase II study evaluating neoadjuvant atezolizumab with gemcitabine and cisplatin; 27 of 39 patients (69%) were < pT2N0 and 16 (41%) pT0N0. No patient with < pT2N0 relapsed and four (11%) with ≥ pT2N0 relapsed with a median follow-up of 16.5 months (range: 7.0–33.7 months) [307]. A third phase II study evaluating NAC with GC plus durvalumab including adjuvant durvalumab with a primary endpoint of EFS demonstrated EFS at 3 years of 73% (95% CI, 59 to 83). Complete pathologic response was achieved in 17 of 52 patients (33%), and 31 (60%) had pathologic response <ypT2 ypN0. Overall survival (OS) was 81% (95% CI, 67 to 89) at 3 years. With the promising pathologic response rates, several larger studies are currently investigating the potential role for neoadjuvant chemo-immunotherapy in patients with MIBC [308].

At present, the results with immunotherapy alone, or in combination with chemotherapy, are promising but not yet approved in routine practice.

7.1.5. Summary of evidence and guidelines for neoadjuvant therapy

7.2. Pre- and post-operative radiotherapy in muscle-invasive bladder cancer

7.2.1. Post-operative radiotherapy

Given the high rates of local-regional failure after RC in patients with locally-advanced (pT3–4) BC, estimated at ~30%, as well as the high risk of distant failure and poor survival for these patients, there is an interest in adjuvant therapies that address both the risk of local and distant disease. Data on adjuvant RT after RC are limited and further prospective studies are needed, but a more recent phase II trial compared adjuvant sequential chemotherapy and radiation vs. adjuvant chemotherapy alone in 120 patients with locally-advanced disease and negative margins after RC (with one or more risk factors: ≥ pT3b, grade 3, or node-positive), in a study population with 53% UC and 47% SCC. Addition of adjuvant RT to chemotherapy alone was associated with a statistically significant improvement in local relapse-free survival (at 2 years 96% vs. 69% favouring the addition of RT). Disease-free survival and OS also favoured the addition of RT, but those differences were not statistically significant and the study was not powered for those endpoints. Late-grade ≥ 3 GI toxicity in the chemoradiation arm was low (7% of patients) [309].

A 2019 systematic review evaluating the efficacy of adjuvant radiation for BC or UTUC found no clear benefit of adjuvant radiation following radical surgery (e.g., cystectomy), although the combination of adjuvant radiation with chemotherapy may be beneficial in locally-advanced disease [310].

Adjuvant radiation might be considered in patients with pT3/pT4 pN0–2 urothelial BC following RC, although this approach has been evaluated in only a limited number of studies without conclusive data demonstrating improvements in OS. Radiation fields should encompass areas at risk for harbouring residual microscopic disease based on pathologic findings at surgery and may include the cystectomy bed and pelvic LNs. Doses in the range of 45 to 50.4 Gy may be considered. A phase II trial with 72 patients showed that a dose of 50.4 of radiotherapy Gy can be used with acceptable toxicity and a high rate of local control [311]. A small retrospective study of 25 patients (median age 64 years) evaluated acute and late toxicity of moderate doses of pelvic RT (range, 45–50.4 Gy). After a median follow-up of 10.4 months the authors concluded that orthotopic ileal neobladders can tolerate moderate radiation doses without significant induced morbidity. Most of the acute GI toxicity seen was grade 1, four patients developed acute grade 2 toxicity; three of whom had been treated by NAC [312]. For patients not treated with NAC, it may be reasonable to sandwich adjuvant radiation between cycles of adjuvant chemotherapy. The safety and efficacy of concurrent radiosensitising chemotherapy in the adjuvant setting needs further study.

7.2.2. Pre-operative radiotherapy

To date, six RCTs have been published investigating pre-operative RT, although all are from several decades ago. In the largest trial, pre-operative RT at a dose of 45 Gy was used, resulting in a significant increase in pathological complete response (9% to 34%) in favour of pre-operative RT, which was also a prognostic factor for survival [313]. The OS data were difficult to interpret since chemotherapy was used in a subset of patients only and more than 50% of patients (241/475) did not receive the planned treatment and were excluded from the final analyses. Two smaller studies using a dose of 20 Gy showed only a small survival advantage in ≥ T3 tumours [314,315]. Two other small trials confirmed downstaging after pre-operative RT [316,317]. In a retrospective analysis of 1,846 evaluable patients, only 34 patients received RT prior to orthotopic neobladder reconstruction. The authors conclude that following pelvic RT, a neobladder is possible in highly selected patients with statistically similar peri-operative complication rates compared to patients who did not receive prior RT. Patient selection, with oncologic factors (positive urethral margins, nodal involvement, and extravascular disease) more commonly than technical factors (adhesions/difficult dissection, bleeding, urethral stricture) influencing conversion from a planned neobladder reconstruction [318].

A meta-analysis of five RCTs showed a difference in 5-year survival (OR: 0.71, 95% CI: 0.48–1.06) in favour of pre-operative RT [319]. However, the meta-analysis was potentially biased by data from the largest trial in which patients were not given the planned treatment. When the largest trial was excluded from the analysis, the OR became 0.94 (95% CI: 0.57–1.55), which was not significant.

A more recent RCT, comparing pre-operative vs. post-operative RT and RC (n = 100), showed comparable OS, DFS and complication rates [320]. Approximately half of these patients had UC, while the other half had SCC. In general, such older data is limited in being able to provide a robust evidence base for modern guideline recommendations.

7.2.3. Local therapy (surgery or radiotherapy) in oligometastatic disease

The other disease state for which there may be an emerging role for adding local therapy Is oligometastatic bladder cancer. Oligometastatic status is defined as a situation with a limited number of metastatic sites. In a recent consensus, a maximum of three metastatic sites, all either resectable or amenable to stereotactic therapy, was proposed as the definition of oligometastatic bladder cancer [321]. Studies from other tumour types (prostate cancer, colorectal cancer and lung cancer) suggest possible survival benefit when adding local therapy. In bladder cancer, some retrospective studies suggest a potential survival benefit when incorporating local therapy to the bladder (including radiation therapy over chemotherapy alone) in metastatic disease [322,323], and when employing metastasis-directed therapy. [324-327] A favourable response to systemic treatment was proposed as the criterion for selection of patients for any metastasis-directed therapy [321]. However, the data in oligometastatic disease are limited and further prospective study in bladder cancer patients is needed.

7.2.4. Summary of evidence and guidelines for pre- and post-operative radiotherapy

7.3. Radical surgery and urinary diversion

7.3.1. Removal of the tumour-bearing bladder

7.3.1.1. Introduction

For decades, the standard treatment for patients with MIBC consisted of RC, pelvic LN dissection, and urinary diversion, with or without NAC [603]. However, an increasing focus on quality of life contributes to a growing trend to use bladder-sparing approaches such as RT or TMT in selected patients (see section 7.5). A multi-institutional propensity score matched and weighted analysis showed comparable oncological outcomes between radical cystectomy and TMT for selected MIBC patients [328]. Performance status and life expectancy obviously influence the choice of primary treatment, as does the type of urinary diversion, with RC being reserved for patients with longer life expectancy without concomitant disease and better PS.

7.3.1.2. Radical cystectomy: timing

A meta-analysis including 19 studies concluded that a delay of > 3 months has a negative effect on OS (HR: 134, 95% CI: 1.18–1.53). Authors highlighted the lack of standardisation regarding the definition of delays which made it impossible to identify a clear cut-off time [329]. Overall conclusion was that BC patients scheduled for RC should be treated without delays to maximise survival.

7.3.2. Radical cystectomy: indications

Radical cystectomy is recommended in patients with T2–T4a, N0M0 disease, very high-risk NMIBC, BCG- refractory, BCG-relapsing and BCG-unresponsive NMIBC (see EAU Guidelines on Non-muscle-invasive Bladder Cancer [2]), as well as extensive papillary disease that cannot be controlled with TURBT and intravesical chemotherapy/immunotherapy alone.

Salvage cystectomy is indicated in non-responders to conservative therapy, i.e., recurrence after bladder-sparing treatment. It is also used as a purely palliative intervention, including for fistula formation, pain and recurrent uncontrollable haematuria (see Section 7.4.1 - Palliative cystectomy).

7.3.3. Radical cystectomy: technique and extent

Different approaches have been described to improve voiding and sexual function in patients undergoing RC for BC. No consensus exists regarding which approach preserves function best. Concern remains regarding the impact of ‘sparing-techniques’ on oncological outcomes.

7.3.3.1. Radical cystectomy in men

In men, standard RC includes removal of the bladder, prostate, seminal vesicles, distal ureters, and regional LNs.

7.3.3.1.1. Concomitant prostate cancer

A systematic review and meta-analysis of 13,140 patients showed an incidental prostate cancer rate of 24% [330]. Incidental prostate cancer was associated with higher age and lower 5-year OS. However, the lower OS can be explained by the higher age of patients with incidental prostate cancer. Pathological reporting of the specimens should follow the recommendations as presented in the EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer [331].

7.3.3.1.2. Sexual-preserving techniques

Four main types have been described:

1. Prostate sparing cystectomy: part of or the whole prostate is preserved including seminal vesicles, vas deferens and neurovascular bundles.

2. Capsule sparing cystectomy: the capsule or peripheral part of the prostate is preserved with adenoma (including prostatic urethra) removed by TURP or en bloc with the bladder. Seminal vesicles, vas deferens and neurovascular bundles are also preserved.

3. Seminal sparing cystectomy: seminal vesicles, vas deferens and neurovascular bundles are preserved.

4. Nerve-sparing cystectomy: the neurovascular bundles are the only tissue left in place.

The systematic review on oncological and functional outcomes of sexual function-preserving cystectomy in men indentified 12 studies (n = 1,098) [332]. In the majority of cases, an open surgical approach was used and the urinary diversion of choice was an orthotopic neobladder. Median follow-up was longer than three years in nine studies, with three studies presenting results with a median follow-up longer than five years.

The majority of the studies included patients who were potent pre-operatively with organ-confined disease without tumour in the bladder neck and/or prostatic urethra. Prostate cancer was ruled out in all of the sexual- preserving cystectomy (SPC) techniques, except in the nerve-sparing approach [331].

Oncological outcomes did not differ between groups in any of the comparative studies that measured local recurrence, metastatic recurrence, DSS and OS, at a median follow-up of three to five years.

For techniques preserving prostatic tissue (prostate- or capsule-sparing), rates of incidental prostate cancer in the intervention group ranged from 0–15%. Incidental prostate cancer with ISUP grade ≥ 4 was not reported.

Post-operative potency was significantly better in patients who underwent any type of SPC technique compared to conventional RC (p < 0.05), ranging from 80–90%, 50–100% and 29–78% for prostate-, capsule- or nerve-sparing techniques, respectively. Urinary continence, defined as the use of ‘no pads’ in the majority of studies, ranged from 88–100% (day-time continence) and from 31–96% (night-time continence) in the prostate-sparing cystectomy patients. No major differences were seen with regard to continence rates between any of these approaches.

The evidence base suggest that these procedures may yield better sexual outcomes than standard RC without compromising oncological outcomes. However, the overall quality of the evidence was moderate, and hence if a SPC technique is offered, patients must be carefully selected, counselled and closely monitored.

7.3.3.1.3. Summary of evidence and recommendations for sexual-preserving techniques in men

7.3.3.2. Radical cystectomy in women

Historically, standard RC in women includes removal of the bladder, the entire urethra and adjacent vagina, uterus, distal ureters, and regional LNs. Pelvic floor disorders, sexual and voiding dysfunction in female patients are prevalent after RC [333]. As part of the pre-operative evaluation a gynaecological history should be obtained and patients should be counselled on the potential negative impact of RC on sexual function and/ or vaginal prolapse. Most importantly, a history of cervical cancer screening, abnormal vaginal bleeding and a family history of breast and/or ovarian cancer should be recorded, as well as ruling out possible pelvic organ prolapse. Post-operatively, screening for sexual and urinary function and prolapse, is mandatory.

Pelvic organ-preserving techniques involve preserving the neurovascular bundle, vagina, uterus, ovaries or variations of any of the stated techniques. From an oncological point of view, concomitant malignancy in gynaecological organs is rare and local recurrences reported after RC are infrequent [334,335]. In premenopausal women, by preserving ovaries, hormonal homeostasis will be preserved, decreasing risk of cognitive impairment, cardiovascular diseases and loss of bone density. In case of an increased risk of hereditary breast or ovarian cancer (i.e., BRCA1/2 mutation carriers or patients with Lynch syndrome), salpingooophorectomy should be advised after childbearing and to all women over 40 years of age [336]. On the other hand, preservation of the uterus and vagina will provide the necessary support for the neobladder, thereby reducing the risk of urinary retention. It also helps to avoid post-operative prolapse as removal of the uterus predisposes to an anterior or posterior vaginal prolapse. In case of an already existing prolapse of the uterus, either isolated or combined with a vaginal prolapse, removing the uterus will be beneficial. It is noteworthy that by resecting the vaginal wall, the vagina shortens which could impair sexual satisfaction and function.

Based on retrospective low quality data only, a systematic review evaluating the advantages and disadvantages of sexual-function preserving RC and orthotopic neobladder in female patients concluded that in well-selected patients, sparing female reproductive organs during RC appears to be oncologically safe and provides improved functional outcomes [337]. Historically, patients selection has been limited to cT2 disease, but there are recent encouraging reports that support including women with more advanced T-stage and histological subtypes without compromising oncological outcomes [338]. Nevertheless, a cross-sectional survey of more than 100 members of the US Society of Urologic Oncology identified significant gaps in adoption of sexual preserving techniques fo rwomen with organ-confined disease; however, in 80% a non-sexual preserving technique was still applied [339].

Pelvic organ-preserving RC could be considered also in elderly and fragile patients as it may be beneficial from the point of reduced blood loss and quicker bowel recovery [340]. Nevertheless, a cross-sectional study among more than 100 members of the Society of Urologic Oncology showed that in the US a non-sex-sparing technique is still used in 80% of cases [339].

7.3.3.2.1. Summary of evidence and recommendations for sexual-preserving techniques in women

7.3.4. Lymphadenectomy: role and extent

The optimal extent of lymphadectomy (LND) has not been established to date. Standard LND in MIBC patients involves removal of nodal tissue cranially up to the common iliac bifurcation, with the ureter being the medial border, and including the internal iliac, presacral, obturator fossa and external iliac nodes. The lateral borders are the genitofemoral nerves, caudally the circumflex iliac vein, the lacunar ligament and the LN of Cloquet [341]. Limited LND includes the nodes from the true pelvis, but excluding the deep obturator nodes. Extended LND includes the same boundaries as a standard LND, except for the cranial limit which is the region of the aortic bifurcation [342]. A super-extended LND extends cranially to the level of the inferior mesenteric artery [343].

Controversies in the clinical importance of LND are related to the question whether it should be considered a staging tool, a therapeutic procedure, or both.

7.3.4.1. Diagnostic value of lymphadenectomy

To understand the lymphatic spread in MIBC, two important autopsy studies have been performed. The first study analysed 367 patients with a history of cystectomy or MIBC at the time of autopsy. In total, 215 patients (59%) had node-positive disease [344]. In these patients 92% of the positive LNs were regional (perivesical or pelvic), 72% retroperitoneal and 35% abdominal.

The second autopsy study focused on the nodal yield when super-extended pelvic LND was performed. Substantial inter-individual differences were found with counts ranging from 10 to 53 nodes [345]. These findings demonstrate the limited utility of node count as a surrogate for extent of dissection, supporting a template-based LND instead.

In addition to autopsy studies, several authors adressed the spread of lymphatic disease by performing LN mapping studies in MIBC patients undergoing RC and (super)extended PLND [346-348]. These studies have demonstrated that LN-positive disease is present in approximately 25% of patients. In the group of node- positive patients, positive LNs cranial to the iliac bifurcation were present in over 40% of patients, however, skip LN metastasis were very rare (1%), as seen in autopsy studies. From a staging perspective only, these studies suggest that a standard LND should be sufficient to identify nearly all patients with node-positive disease.

7.3.4.2. Therapeutic value of lymphadenectomy

The therapeutic value of LND is a topic of continuous debate. To assess the oncological outcomes of different LND templates, a systematic review including 19 studies was performed [349]. Five studies compared LND vs. no LND and reported better oncological outcomes for the LND group. Seven out of twelve studies comparing (super)extended with limited or standard LND reported a beneficial outcome for (super)extended LND in at least a subset of patients. Two studies did not show a difference in outcome between extended and super-extended LND [349].

The two prospective randomised trials investigating the anatomic extend of the LND are the German LEA trial and the US/Canadien SWOG S1011 trial. In the LEA trial, patients with MIBC (n = 346) or T1G3 disease (n = 55) were included. Patients underwent either a limited LND (n= 203) or extended LND (n = 198). Survival differences between the groups were seen, in favour of extended LND. However, extended LND failed to show a significant advantage (the trial was designed to show an absolute improvement of 15% in 5-year RFS by extended LND) over limited LND for RFS, CSS, and OS. The results of the SWOG S1011 trial comparing standard versus extended LND, presented at the 2023 ASCO meeting, showed in patients with clinically localised bladder cancer after a median six years follow-up no DFS (HR 1.10 [95%CI 0.87-1.42] p=0.4) or OS (HR 1.15 [95%CI 0.89-1,48] p=0.29) benefit for an extended LND. It does, however, increase the risk of side effects and post-operative mortality.

In conclusion, based on these two RCT’s, an extended LND, is not associated with improved survival and increases the risk of morbidity.

7.3.5. Robotic-assisted laparoscopic cystectomy

A 2019 Cochrane SR of five RCTs compared robotic radical cystectomy (RARC) with extacorporeal urinary diversion and open radical cystectomy (ORC) [350]. One study included an laparoscopic radical cystectomy arm (LRC) [351]. No differences were found in complications, time to recurrence, QoL and surgical margin rate for RARC and ORC. RARC was associated with lower transfusion rate and shorter length of hospital stay (median 0.7 days). The study had very-low to moderate certainty of evidence.

In 2023, an updated SR and meta-analysis was published including eight RCTs of which three studies performed intracorporeal urinary diversion [352]. The ERAS pathway was adopted in one study with extracorporeal urinary diversion and in three studies with intracorporeal urinary diversion [351,353-355]. The following outcomes were reported:

• Longer length of hospital stay for ORC (0.2 days); however, differences were seen depending on geographical location. In four USA and two UK trials longer hospital stay for ORC was reported (0.6 and 1.5 days, respectively) whilst in two EU based trials longer hospital stay for RARC was reported (0.9 days).
• Higher venous trombo-events (OR 1.8) and transfusion rates (0.5 blood units) for ORC.
• Longer operative time for RARC (mean difference: 76 min).
• No differences in 90-day complication rate and post-operative ileus rate.
• No differences in positive surgical margin rate.
• No differences in QoL except for the domain of phsyical functioning favouring RARC.
• No differences in OS and RFS (median follow-up time: 36 months).

It should be noted that the meta-analysis did not distinguish between intracorporeal and extracorporeal approaches for urinary diversion in the RARC group.

Long-term oncological outcomes were also reported in a large (n = 595) single-centre study with a median follow-up of over five years. In this study comparable recurrence and survival data, including atypical recurrences (defined as one or a combination of the following: portsite metastasis or peritoneal carcinomatosis) [356]. Interrestingly, another study detected residual cancer cells in pelvic washing specimens during or after, but not before, RARC in approximately half of the patients (9/17), which was associated with aggressive histological subtypes and cancer recurrence; however, these findings requirer confirmation in larger studies [357].

An economic evaluation (healthcare and societal perspective) of a Dutch prospective multi-centre comparative effectiveness study asessing ORC (n = 168) vs. RARC (n = 180) showed that both mean healthcare costs and societal costs per patient were significantly higher after RARC, resulting in an increase in QALYs of 0.02 [358].

Data on post-RC uretero-enteric stricture rates for both ORC and RARC remain inconclusive. Results are mainly reported by high-volume centres or derive from population-based studies with a large variety of endpoints and poor controlling of potential confounders, making comparison difficult [359-363]. Especially those managed by extracorporeal diversion (RARC-ECUD) tend to have more strictures compared to intracorporeal diversion (RARC-ICUD) [363]. This is explained by the need for more extensive dissection of ureter in RARC-ECUD, more tension, resulting in impaired blood supply [364,365].

7.3.5.1. Summary of evidence and guidelines for robotic-assisted laparoscopic cystectomy

7.3.6. Urinary diversion after radical cystectomy

Different types of segments of the intestinal tract can be used to reconstruct the urinary tract, including the ileum, colon and appendix, with ileum used in most cases. Several studies have compared advantages and disadvantages in terms of QoL, sexual function, urinary continence and body image between different urinary diversions [366], but further research evaluating the impact of tumour stage, functional- and socio-economic status are needed.

7.3.6.1. Different types of urinary diversion

For the choice of urinary diversion, comorbidity, cardiac, pulmonary and cognitive function are important factors that should be considered, along with the patient’s social support and preference (see Section patient selection/comorbidities). Age > 80 years is often considered to be the threshold after which neobladder reconstruction is not recommended. However, there is no exact age for a strict contraindication [367]. Randomised controlled trials comparing conduit diversion with neobladder or continent cutaneous diversion have not been performed.

7.3.6.1.1. Uretero-cutaneostomy

Ureteral diversion to the abdominal wall is the simplest form of cutaneous diversion. Operating time, complication rate, blood loss, transfusion rate, stay at intensive care and length of hospital stay are lower in patients treated with ureterocutaneostomy as compared to ileal conduit [368]. In frail patients and/or in those with a solitary kidney who need a supravesical diversion, uretero-cutaneostomy is the preferred procedure. In case patients have both kidneys and need a uretero-cutaneostomy, either one ureter, to which the other shorter one is attached end-to-side, is connected to the skin (trans-uretero-cutaneostomy) or both ureters may be directly anastomosed to the abdominal wall creating a stoma.

Due to the smaller diameter of the ureters, stoma stenosis and ascending UTIs have been observed more frequently for this technique as compared to using small or large bowel to create an intestinal stoma [369].

7.3.6.1.2. Ileal conduit

The ileal conduit is an established option with well-known/predictable results. Early complications (30-day cut off, used in most publications) include UTIs, pyelonephritis, ureteroileal leakage and stenosis which occur in 48% of patients [370].

7.3.6.1.3. Orthotopic neobladder

According to Dutch-, German- and Spanish bladder cancer registry data, an orthotopic bladder substitution to the urethra is used in approximately 10–20% of both male and female patients. Emptying of the reservoir anastomosed to the urethra requires abdominal straining, and sphincter relaxation. The terminal ileum is the GI segment most often used for orthotopic bladder substitution. Early and late morbidity in up to 22% of patients is reported [371].

Various forms of UUT reflux protection, including a simple isoperistaltic tunnel, ileal intussusception, tapered ileal prolongation implanted subserosally, and direct (sub)mucosal or subserosal ureteral implantation, have been described [372,373]. According to the long-term results, the UUT is protected sufficiently by either method [371].

A study comparing cancer control and patterns of disease recurrence in patients with neobladder and ileal conduit showed no difference in CSS between the two groups when adjusting for pathological stage [374]. Urethral recurrence in neobladder patients seems rare (0.8–13.7% [pooled estimate of 4.6% in both male and female patients, also considering the significantly higher recurrence rates in male patients]) [375]. These results indicate that neobladder in male and female patients does not compromise the oncological outcome of cystectomy.

7.3.6.1.4. Continent cutaneous urinary diversion

Continent cutaneous urinary diversion (a low-pressure detubularised ileal reservoir for self-catheterisation) and uretero-rectosigmoidostomy are rarely used techniques nowadays, due to their high complication rates, including stomal stenosis, incontinence in the continent cutaneous diversion, UUT infections and stone formation in case of uretero-rectosigmoidostomy [376].

7.3.6.2. Patient selection

Ensuring that patients make a well-informed decision about the type of urinary diversion is associated with less decision regret post-operatively, independent of the method selected [377]. Therefore, all applicable forms of urinary diversion should be discussed, taking into account patient preference, comorbidities, age and tumour characteristics.

Diagnosis of an invasive urethral tumour prior to cystectomy leads to urethrectomy which is a contraindication for a neobladder reconstruction. Non-muscle-invasive BC in prostatic urethra or bladder neck biopsies does not necessarily preclude orthotopic neobladder substitution, provided that patients undergo regular follow-up cystoscopy and urinary cytology [378]. In women undergoing RC the rate of concomitant urethral malignancy has been reported to range from 12–16% [379]. Localisation of the primary tumour at the bladder neck correlated strongly with concomitant urethral malignancy. Bladder neck biopsies prior to RC are important in women scheduled for an orthotopic bladder substitute [380].

In the presence of positive LNs, orthotopic neobladder can be considered in case of N1 disease, but not in N2 or N3 tumours [381].

Oncological results after orthotopic neobladder or illial conduit are similar in terms of local or distant metastasis recurrence, but secondary urethral tumours seem less common in patients with a neobladder compared to those with conduits or continent cutaneous diversions [382].

Patients undergoing continent urinary diversion must be motivated to learn about their diversion and to be manually skilful to be able to deal with their diversion. Contraindications to continent urinary diversions include:

• debilitating neurological and psychiatric illnesses;
• limited life expectancy;
• severe impaired liver or renal function.

Relative contraindications for an orthotopic neobladder are high-dose pre-operative RT, complex urethral strictures and severe urethral sphincter-related incontinence [383].

A retrospective study including 1,383 patients showed that the risk of a decline in estimated glomerular filtration rate (eGFR) did not significantly differ after ileal conduit vs. neobladder in patients with pre- operative chronic kidney disease 2 (eGFR 60–89 mL/min/1.73 m2) or 3a (eGFR 45–59 mL/min/1.73 m2) [384]. Only age and anastomotic strictures were found to be associated with a decline in eGFR.

Currently, it is not possible to recommend a particular type of urinary diversion. However, most institutions prefer ileal orthotopic neobladders and ileal conduits based on clinical experience. In selected patients, such as patients with a single kidney, uretero-cutaneostomy is surgically the least burdensome type of diversion. Recommendations related to RC and urinary diversions are listed in Section 7.3.10.

7.3.6.3. Peri-operative care

Similar to other tumour types, such as colorectal cancer, the application of a multimodal prehabilitation programme (i.e. physiotherapy, nutritional intervention, cessation of smoking) may improve patient health status prior to surgery and subsequently reduce postoperative complication rates [385]. However, evidence on this is limited and randomised controlled trials are missing.

Patients treated according to a ‘Fast track’/ERAS (Early Recovery After Surgery) protocol have shown to score better on the emotional and physical functioning scores and suffer less from wound healing disorders, fever and thrombosis [386].

Pre-operatively, the ERAS protocol recommends no bowel prepation or fasting. Other components are, for example, same day admission, as well as carbohydrate loading and a pre-operative exercise programme.

Important post-operative components of the ERAS protocol are pain management, which involves reducing the use of opioids; increasing the use of high-dose acetaminophen and/or ketorolacs (only as breakthrough pain medication) and patients on ERAS experience more pain as compared to patients on a traditional protocol (Visual Analogue Scale [VAS] 3.1 vs. 1.1, p < 0.001), but post-operative ileus decreased from 22% to 7.3% (p = 0.003) [387].

Venous thromboembolism (VTE) prophylaxis may be implemented as part of an ERAS protocol. A single- centre non-randomised study showed a significant lower 30-day VTE incidence rate in patients treated for 28 days with enoxaparin compared to patients without prophylaxis [388]. Data from the Ontario Cancer Registry including 4,205 cystectomy patients of whom 1,084 received NAC showed that VTE rates are higher in patients treated with NAC as compared to patients treated with cystectomy only (12% vs. 8%, p = 0.002) [389].

7.3.7. Morbidity and mortality

In four retrospective studies and one population-based cohort study, the peri-operative mortality after RC was reported as 2.1–3.2% at 30 days and 3.4–8.0% at 90 days [390,391]. Morbidity rates differ strongly according to the reporting system used. Using the Clavien-Dindo Classification system complication rates ranged from 50–88% (I–IV) and severe complications from 30–42% (≥ III) [392-395]. In large national databases and institutional series, readmission rates are approximately 25% within 30 days of discharge [396]. Late morbidity was usually linked to the type of urinary diversion (see also above). Early morbidity associated with RC for NMIBC (at high risk for disease progression) is similar and no less than that associated with muscle-invasive tumours [397,398]. In general, lower morbidity and (peri-operative) mortality have been observed by surgeons and in hospitals with a higher case load and therefore more experience [399-402]. A retrospective analysis of 1,303 patients managed in 7 (non-academic) Dutch hospitals revealed variation in treatment preferences between them; however, despite this there was no significant difference in overall survival [403].

Table 7.1: Management of neobladder morbidity (30-64%) [404]

¹ A systematic review showed that peri-operative blood transfusion (PBT) in patients who undergo RC correlates with increased overall mortality, CSM and cancer recurrence. The authors hypothesised that this may be caused by the suggested immunosuppressive effect of PBT. In a retrospective study, Buchner and co-workers showed 5-year decreased CSS in cases where intra-operative blood transfusion (CSS decreased from 67% to 48%) or post-operative blood transfusion (CSS decreased from 63% to 48%) were given [405]
² Hammond and co-workers reviewed 20,762 cases of VTE after major surgery and found cystectomy patients to have the second-highest rate of VTE among all cancers studied [406]. These patients benefit from 30 days low-molecular-weight heparin prophylaxis. Subsequently, it was demonstrated that BMI > 30 and non-urothelial BCs are independently associated with VTE after cystectomy. In these patients extended (90 days) heparin prophylaxis should be considered [406].

7.3.8. Survival

Of all cancers, bladder cancer ranks 13th in terms of mortality, with rates decreasing particularly in the most developed countries [407].

Disease-free survival and OS in a large population-based study was 35% and 58% at ten years, respectively [408]. However, the 5-year OS in node-positive patients who underwent cystectomy was 18% [409].

A systematic review including 57 studies (n = 30,293) assessed the long-term survical of patients treated with trimodality therapy (TMT) and RC [408]. Ten-year OS was 30.9% and 35.1%, for TMT and RC, respectively with a mean DSS of 50.9% for TMT and 57.8% for RC. For T2 disease, 10-year DSS was 69% and 78.9% for TMT and RC, respectively and for T3/T4 disease 43.5% and 43.1% for TMT and RC, respectively. Three percent of the patients (812 of 27,867) received NAC, resulting in 5-year OS and DSS in downstaged patients (≤ pT1) at RC of 75.7% and 88.3%, respectively.

7.3.9. Impact of hospital and surgeon volume on treatment outcomes

In a systematic review including 40 retrospective studies with 56,000 patients, the impact of hospital and/or surgeon volume and peri-operative outcomes of RC was assessed [410]. A higher hospital volume was associated with lower in-hospital, 30-day and 90-day mortality. In addition, higher volume hospitals were more likely to have lower positive surgical margins, higher number of LNDs and neobladders and lower complication rates. For surgeon volume, less evidence was available. This study suggested performing at least 10 RCs per centre annually and preferably more than 20. Recently, a nationwide analysis of the Dutch Cancer Registry including almost 9,500 patients between 2008 and 2018 reported decreased 30- and 90-day mortality rates for annual hospital volumes of > 30 RCs. Furthermore, this study showed no true plateau curve for 30- and 90-day mortality beyond 30 RCs supporting the ‘more is better’ principle [411,412].

7.3.10. Summary of evidence and guidelines for radical cystectomy and urinary diversion

Figure 7.1: Flow chart for the management of T2–T4a N0M0 urothelial bladder cancer

CT = computed tomography; MRI = magnetic resonance imaging; UUT = upper urinary tract.

7.4. Palliative and salvage cystectomy

Unresectable locally-advanced tumours (T4b, invading the pelvic or abdominal wall) may be accompanied by debilitating symptoms, including bleeding, pain, dysuria and urinary obstruction. These patients are candidates for palliative treatments, such as palliative RT. If control of the symptoms is not possible by less invasive methods, patients may be offered a palliative cystectomy with urinary diversion or urinary diversion only. Palliative cystectomy carries the greatest morbidity, particularly in patients with a poor PS. In a series of 74 patients who underwent palliative cystectomy, severe complications (Clavien-Dindo grade ≥ 3) occurred in 30%. The 30-day mortality rate was 9% and at eight months follow-up, 70% had died [413].

In a retrospective single-centre analysis, Pieretti et al., grouped 265 patients into salvage cystectomy post-TMT, primary cystectomy or primary cystectomy with prior history of non-TMT abdominal or pelvic RT. Post-TMT salvage cystectomy was associated with a higher incidence of any late (HR: 2.3, p = 0.02) and major late complications (HR: 2.1, p < 0.05) but there was no difference in DSS (p = 0.8) or OS (p = 0.9) between the groups [414].

7.4.1. Guidelines for palliative and salvage cystectomy

7.4.1.1. EAU-ESMO consensus statements on the management of advanced- and variant bladder cancer [81,82]*

*Only statements which met the a priori consensus threshold across all three stakeholder groups are listed (defined as ≥ 70% agreement and ≤ 15% disagreement, or vice versa).

7.4.2. Supportive care

7.4.2.1. Obstruction of the upper urinary tract

Unilateral (best kidney) or bilateral nephrostomy tubes provide the easiest solution for UUT obstruction, but patients find the tubes inconvenient and prefer ureteral stenting. However, stenting can be difficult to achieve. Stents must be regularly replaced and there is the risk of stent obstruction or displacement. Another possible solution is a urinary diversion with, or without, a palliative cystectomy.

7.4.2.2. Bleeding and pain

In the case of bleeding, the patient must be screened first for coagulation disorders or the patient’s use of anticoagulant drugs must be reviewed. Transurethral (laser) coagulation may be difficult in a bladder full of tumour or with a bleeding tumour. Intravesical rinsing of the bladder with 1% silver nitrate or 1–2% alum can be effective [415]. This can usually be done without any anaesthesia. The instillation of formalin (2.5–4% for 30 minutes) is a more aggressive and painful procedure, requiring anaesthesia. Formalin instillation has a higher risk of side-effects, e.g., bladder fibrosis, but is more likely to control the bleeding [415]. Vesicoureteral reflux should be excluded to prevent renal complications.

Radiation therapy is another common strategy to control bleeding and is also used to control pain. An older study reported control of haematuria in 59% of patients and pain control in 73% [416]. Irritative bladder and bowel complaints due to irradiation are possible, but are usually mild. Non-conservative options are embolisation of specific arteries in the small pelvis, with success rates as high as 90% [415]. Radical surgery is a last resort and includes cystectomy and diversion (see above, Section 7.4.1).

7.5. Bladder-sparing treatments for localised disease

7.5.1. Transurethral resection of bladder tumour

Transurethral resection of bladder tumour alone in MIBC patients is only possible as a therapeutic option if tumour growth is limited to the superficial muscle layer and if re-staging biopsies are negative for residual (invasive) tumour [417]. In general, approximately 50% of patients will still have to undergo RC for recurrent MIBC with a disease-specific mortality rate of up to 47% in this group [418]. A disease-free status at re-staging TURB appears to be crucial in making the decision not to perform RC [419,420]. A prospective study by Solsona et al., including 133 patients after radical TURB and re-staging negative biopsies, reported a 15-year follow-up [420]. Thirty per cent of patients had recurrent NMIBC and went on to intravesical therapy, and 30% (n = 40) progressed, of which 27 died of BC. After five, ten, and fifteen years, the results showed CSS rates of 81.9%, 79.5%, and 76.7%, respectively and PFS rates with an intact bladder of 75.5%, 64.9%, and 57.8%, respectively.

In conclusion, TURB alone should only be considered as a therapeutic option for muscle-invasive disease after radical TURB, when the patient is unfit for cystectomy, or refuses open surgery, or as part of a TMT bladder-preserving approach.

7.5.1.1. Guideline for transurethral resection of bladder tumour

7.5.2. External beam radiotherapy

Current RT techniques with soft-tissue matching and image guidance result in superior bladder coverage and a reduced integral dose to the surrounding tissues. The target total dose (to bladder and/or bladder tumour) for curative EBRT in BC is 64–66 Gy [421,422]. A reasonable alternative is moderately hypofractionated EBRT to 55 Gy in 20 fractions which has been suggested to be non-inferior to 64 Gy in 32 fractions in terms of invasive locoregional control, OS, and late toxicity. In a phase II study, 55 patients (median age 86) with BC, unfit for cystectomy or even daily RT, were treated with 6-weekly doses of 6 Gy [423]. Forty-eight patients completed EBRT with acceptable toxicity and 17% showed local progression after two years demonstrating good local control with this more ultra-hypofractionated schedule.

Elective treatment to the LNs is optional and should take into account patient comorbidities and the risks of toxicity to adjacent critical structures. For node-positive disease, consider boosting grossly involved nodes to the highest achievable dose that does not violate normal tissue constraints based on the clinical scenario.

The use of modern standard EBRT techniques results in major related late morbidity of the urinary bladder or bowel in less than 5% of patients [424]. Acute diarrhoea is reduced even more with intensity- modulated RT [425]. Important prognostic factors for outcome include response to EBRT, tumour size, hydronephrosis, presence of CIS, and completeness of the initial TURB. Additional prognostic factors reported are age and stage [426].

With the use of modern EBRT techniques, efficacy and safety results seem to have improved over time. A 2002 Cochrane analysis demonstrated that RC has an OS benefit compared to RT [427], although this was not the case in a 2014 retrospective review using a propensity score analysis [428].

In a 2017 retrospective cohort study of U.S. National Cancer Database data, patients over 80 were identified with cT2–4, N0–3, M0 BC, who were treated with curative EBRT (60–70 Gy, n = 739) or concurrent chemoradiotherapy (n = 630) between 2004 and 2013 [429]. The 2-year OS was 42% for EBRT vs. 56% for chemoradiotherapy (p < 0.001). For EBRT a higher RT dose and a low stage were associated with improved OS.

In conclusion, although EBRT results seem to improve over time, EBRT alone does not seem to be as effective as surgery or TMT therapy (see Section 7.5.4). Factors that influence outcome should be considered. However, EBRT can be an alternative treatment in patients unfit for radical surgery or concurrent chemotherapy, and it can also be effective in helping control bleeding.

The results of several studies show that radiotherapy delivered in a hypofractionated regime (such as 21 Gy in 3 fractions evaluated in the MRC BA09 randomised control trial [430], can provide rapid relief of local bladder cancer symptoms, including in particular symptomatic hematuria. Other fractionation regimes include 35 Gy in 10 fractions, 30 Gy in 5 fractions, 36 Gy in 6 fractions given once weekly [431], and even a single 8 Gy fraction. In the palliative setting, symptom resolution typically lasts for the majority of the patients’ remaining lifespan.

7.5.2.1. Summary of evidence and guideline for external beam radiotherapy

7.5.2.2. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer [81,82]*

*Only statements which met the a priori consensus threshold across all three stakeholder groups are listed (defined as ≥ 70% agreement and ≤ 15% disagreement, or vice versa).
IGRT = image-guided radiotherapy; IMRT = intensity-modulated radiotherapy.

7.5.3. Chemotherapy

Chemotherapy alone rarely produces durable complete remissions. In general, a clinical complete response rate of up to 56% is reported in some series, which must be weighed against a staging error of > 60% [432,433]. Response to chemotherapy is a prognostic factor for treatment outcome and eventual survival although it may be confounded by patient selection [434].

Several groups have reported the effect of chemotherapy on resectable tumours (neoadjuvant approach), as well as unresectable primary tumours [263,274,435,436]. Neoadjuvant chemotherapy with two to three cycles of MVAC or CMV has led to a down-staging of the primary tumour in various prospective series [263,274,435].

A bladder-conserving strategy with TURB and systemic cisplatin-based chemotherapy has been reported several years ago and could lead to long-term survival with intact bladder in a highly selected patient population [437].

A recent large retrospective analysis of a U.S. National Cancer Database cohort reported on 1,538 patients treated with TURB and multi-agent chemotherapy [438]. The two and 5-year OS for all patients was 49% and 32.9% and for cT2 patients it was 52.6% and 36.2%, respectively. While these data show that longterm survival with intact bladder can be achieved in a subset of patients it is not recommended for routine use.

7.5.3.1. Summary of evidence and guideline for chemotherapy

7.5.4. Trimodality bladder-preserving treatment

Bladder preservation as an alternative to RC is generally reserved for patients with smaller solitary tumours, no extensive or multifocal CIS, no tumour-related hydronephrosis, and good pre-treatment bladder function. Trimodality bladder-preserving treatment should also be considered in all patients with a contraindication for surgery, either a relative or absolute contraindication since the factors that determine fitness for surgery and chemoradiotherapy differ.

Trimodality therapy combines TURB, chemotherapy and RT. The rationale to combine TURB with RT is to achieve maximal local tumour control in the bladder and adjacent nodes. The addition of radiosensitising chemotherapy or other radiosensitisers (mentioned below) is aimed at the potentiation of RT. Micrometastases are targeted by platinum-based combination chemotherapy (for details see Section 7.1). The aim of TMT is to preserve the bladder and QoL without compromising oncological outcome. There are no definitive contemporary data supporting the benefit of using neoadjuvant or adjuvant chemotherapy combined with chemoradiation. Patient selection is critical in achieving good outcomes [439]. Whether a node dissection should be performed before TMT as in RC remains unclear [81,82].

In the case of TMT, two distinct patterns of care emerge; treatment aimed at patients fit for cystectomy who elect TMT or refuse cystectomy, and treatment aimed at older, less fit, patients. For the former category, TMT presents selective bladder preservation and in this case the initial step is a radical TURB where as much tumour as possible should be resected. In this case appropriate patient selection (e.g., T2 tumours, no CIS) is crucial [440,441]. Even in case of an initial presumed complete resection, a second TUR has been suggested to reveal tumour in > 50% of patients and subsequently improves 5-year OS in case of TMT [442]. For patients who are not candidates for cystectomy, less stringent criteria can be applied, but extensive CIS and poor bladder function should both be regarded as relative contraindications.

A collaborative review has described the principles of TMT [439]. For radiation, two schedules are most commonly used; historically within the RTOG a split-course format with interval cystoscopy [443] and single- phase treatment which is now more commonly used [444]. A conventional radiation schedule includes EBRT to the bladder and limited pelvic LNs with an initial dose of 40-45 Gy, with a boost to the whole bladder of 50–54 Gy and a further tumour boost to a total dose of 60–66 Gy. If not boosting the tumour, it is also reasonable for the whole bladder to be treated to 59.4–66 Gy. For node-positive disease, consider boosting grossly involved nodes to the highest achievable dose that does not violate normal tissue constraints. Therefore, elective treatment to the LNs (when node negative) is optional and should take into account patient comorbidities and the risks of toxicity to adjacent critical structures.

A reasonable radiation dosing alternative to conventional fractionation when treating the bladder-only fields is moderately hypofractionated EBRT to 55 Gy in 20 fractions which has been suggested to be non-inferior to 64 Gy in 32 fractions in terms of invasive loco-regional control, OS and late toxicity [421,445] in a meta-analysis of individual patient data from the BC2001 and BCON studies.

Different concurrent chemotherapy regimens have been used, but most evidence exists for cisplatin [446] and mitomycin-C plus 5-FU [444]. Alternative regimens that have been evaluated include: single agent gemcitabine [447], capecitabine [448] and hypoxia modification with carbogen/nicotinamide [81,82]. In a recently published phase II RCT, twice-a-day radiation plus 5-FU/cisplatin was compared to once-daily radiation plus gemcitabine [447]. Both arms were found to result in a > 75% free from distant metastases rates at 3 years (78% and 84%, respectively). Therefore, there are good chemotherapy options for non-cisplatin candidates such as 5-FU/mitomycin-C or low-dose gemcitabine.

Five-year CSS and OS rates vary between 50%–84% and 36%–74%, respectively, with salvage cystectomy rates of 10–30% [439,440,444,446,449].

There are no successfully completed RCTs comparing the outcome of TMT with RC. The BC2001 trial with 10 year follow-up showed that combined radiotherapy with mitomycin C and fluorouracil significantly improved locoregional control and five year cystectomy rates and non-significantly improved DFS, OS and DSS compared to radiotherapy alone [450] as shown in other studies [443,444,451]. Many of the reported series have differing characteristics as compared to the larger surgical series, which typically have median ages in the mid- to-late 60s compared to mid-70s for some large RT series (reviewed by James, et al. [444]).

As there are no completed randomised trials, RC and TMT have been compared in systematic reviews, meta-analyses, large population-based studies and multi-institutional propensity score matched and weighted analyses [328,408,452]. Overall, in balance, these studies show similar oncological outcomes between radical cystectomy and trimodality therapy for select patients with muscle-invasive bladder cancer. These results support that trimodality therapy, in the setting of multidisciplinary shared decision making, should be offered to all suitable candidates with muscle-invasive bladder cancer and not only to patients with significant comorbidities for whom surgery is not an option [328].

Another study reported no difference in survival outcomes in cN+ patients treated with surgery versus radical RT [453].

The Boston group has also reported on their experience in 66 patients with mixed histological subtypes treated with TMT and found similar complete response, OS, DSS and salvage cystectomy rates as in UC [454]. The majority of recurrences post-TMT are non-invasive and can be managed conservatively [444]. In contemporary series, salvage cystectomy is required in about 10–15% of patients treated with TMT and can be curative [328,440,444,449]. Current data suggest that major late complication rates are slightly higher but remain acceptable for salvage- vs. primary cystectomy [455].

A sub-analysis of two RTOG trials looked at complete response (T0) and near-complete response (Ta or Tis) after TMT [456]. After a median follow-up of 5.9 years 41/119 (35%) of patients experienced a bladder recurrence, and fourteen required salvage cystectomy. There was no difference between complete and near- complete responders. Non-muscle-invasive BC recurrences after complete response to TMT were reported in 25% of patients by the Boston group, sometimes over a decade after initial treatment [457]. A NMIBC recurrence was associated with a lower DSS, although in properly selected patients, intravesical BCG could avoid immediate salvage cystectomy.

Overall significant late pelvic (GI/genitourinary [GU]) toxicity rates after TMT are low and QoL is good [444,458,459]. A combined analysis of survivors from four RTOG trials with a median follow-up of 5.4 years showed that combined-modality therapy was associated with low rates of late grade 3 toxicity (5.7% GU and 1.9% GI). No late grade 4 toxicities or treatment-related deaths were recorded [458]. A retrospective study showed QoL to be good after TMT and in most domains better than after cystectomy, although prospective validations are needed [460]. One option to reduce side effects after TMT is the use of IMRT and image-guided RT (IGRT) [81,82,461].

A bladder-preserving TMT strategy requires very close multidisciplinary cooperation [81,82]. This was also highlighted by a Canadian group [462]. In Ontario between 1994 and 2008 only 10% (370/3,759) of patients with cystectomy had a pre-operative radiation oncology consultation, with high geographical variations. Independent factors associated with this consultation included advanced age (p < 0.001), greater comorbidity (p < 0.001) and earlier year of diagnosis (p < 0.001). A bladder-preserving TMT strategy also requires a high level of patient compliance. Even if a patient has shown a clinical response to a TMT bladder-preserving strategy, the bladder remains a potential source of recurrence, hence long-term life-long bladder monitoring is essential and patients should be counselled that this will be required.

7.5.4.1. Summary of evidence and recommednations for trimodality bladder-preserving treatment

7.5.4.2. EAU-ESMO consensus statements on the management of advanced- and variant bladder cancer  [81,82]*

*Only statements which met the a priori consensus threshold across all three stakeholder groups are listed (defined as > 70% agreement and < 15% disagreement, or vice versa).
HCP = healthcare professional; IGRT = image-guided radiotherapy; IMRT = intensity-modulated radiotherapy;5FU = 5-fluorouracil; MMC = mitomycin-C.

7.6. Adjuvant therapy

7.6.1. Role of adjuvant platinum-based chemotherapy

Adjuvant chemotherapy after RC for patients with pT3/4 and/or LN positive (N+) disease without clinically detectable metastases (M0) is still under debate. The general benefits of adjuvant chemotherapy include:

• chemotherapy is administered after accurate pathological staging, therefore, treatment in patients at low risk for micrometastases is avoided;
• no delay in definitive surgical treatment.

The drawbacks of adjuvant chemotherapy are:

• assessment of in vivo chemosensitivity of the tumour is not possible and overtreatment is an unavoidable problem;
• delay of or intolerability to chemotherapy, due to post-operative morbidity [463].

There is limited evidence from adequately conducted and accrued phase III RCTs in favour of the routine use of adjuvant chemotherapy [464-469]. An individual patient data meta-analysis [470] of survival data from six RCTs of adjuvant chemotherapy [471-473] included 491 patients (unpublished data from Otto et al., were included in the analysis). All included trials suffered from significant methodological flaws including small sample size (underpowered), incomplete accrual, use of inadequate statistical methods and design flaws (irrelevant endpoints and failing to address salvage chemotherapy in case of relapse or metastases) [464]. In these trials, three or four cycles of CMV, cisplatin, cyclophosphamide, and adriamycin (CISCA), methotrexate, vinblastine, adriamycin or epirubicin, and cisplatin (MVA(E)C) and cisplatin with methotrexate (CM) were used [474], and one trial used cisplatin monotherapy [475]. The data were not convincing to support an unequivocal recommendation for the use of adjuvant chemotherapy. In 2014, this meta-analysis was updated with an additional three studies [467-469] resulting in the inclusion of 945 patients from nine trials [466]. None of the trials had fully accrued and individual patient data were not used in the analysis [466]. For one trial only an abstract was available at the time of the meta-analysis [468] and none of the included individual trials were significantly positive for OS in favour of adjuvant chemotherapy. In two of the trials more modern chemotherapy regimens were used (gemcitabine/cisplatin and paclitaxel/gemcitabine/cisplatin) [467,468]. The HR for OS was 0.77 (95% CI: 0.59–0.99, p = 0.049) and for DFS 0.66 (95% CI: 0.45–0.91, p = 0.014) with a stronger impact on DFS in case of nodal positivity. Recently, a systematic review and meta-analysis of individual patient data from RCTs in patients treated with adjuvant cisplatin-based chemotherapy for MIBC was conducted [476]. In an analysis of 10 RCTs (n = 1,183), an OS benefit was demonstrated for cisplatin-based adjuvant chemotherapy (HR: 0.82, 95% CI: 0.70–0.96, p = 0.02). This translates into an absolute improvement in survival of 6% at 5 years, from 50% to 56%, and a 9% absolute benefit when adjusted for age, sex, pT stage, and pN category (HR: 0.77, 95% CI: 0.65–0.92, p = 0.004). Adjuvant chemotherapy was also shown to improve RFS (HR: 0.71, 95% CI: 0.60-0.83, p < 0.001), locoregional RFS (HR: 0.68, 95% CI: 0.55–0.85, p < 0.001), and MFS (HR: 0.79, 95% CI: 0.65–0.95, p = 0.01), with absolute benefits of 11%, 11%, and 8%, respectively.

A retrospective cohort analysis including 3,974 patients after cystectomy and LND showed an OS benefit in high-risk subgroups (extravesical extension and nodal involvement) (HR: 0.75, CI: 0.62–0.90) [477]. A publication of the largest RCT (European Organisation for Research and Treatment of Cancer [EORTC] 30994), although not fully accrued, showed a significant improvement of PFS for immediate, compared with deferred, cisplatin-based chemotherapy (HR: 0.54, 95% CI: 0.4–0.73, p < 0.0001), but there was no significant OS benefit [478]. Furthermore, a large observational study including 5,653 patients with pathological T3–4 and/ or pathological node-positive BC, treated between 2003 and 2006 compared the effectiveness of adjuvant chemotherapy vs. observation. Twenty-three percent of patients received adjuvant chemotherapy with a 5-year OS of 37% for the adjuvant arm vs. 29.1% (HR: 0.70, 95% CI: 0.64–0.76) in the observation group [479]. Another large retrospective analysis based on the U.S. National Cancer Database including 15,397 patients with locally-advanced (pT3/4) or LN-positive disease also demonstrated an OS benefit in patients with UC histology [480]. In patients with concomitant histological subtypes, however, no benefit was found.

Patients should be informed about potential chemotherapy options before RC and the limited evidence for adjuvant chemotherapy.

7.6.2. Role of adjuvant immunotherapy

To determine the benefit of PD-1/PD-L1 checkpoint inhibitors, three phase III RCTs have evaluated checkpoint inhibitor monotherapy with atezolizumab, nivolumab or pembrolizumab in patients with muscle-invasive UC. The CheckMate 274 phase III multi-centre, double-blind, RCT of adjuvant nivolumab vs. placebo for up to 1 year in 709 patients with muscle-invasive UC with a high risk of recurrence (pathological stage pT3, pT4a, or pN+) (neoadjuvant cisplatin-based chemotherapy was allowed before trial entry) demonstrated a significant improvement in median DFS (20.8 months [95% CI: 16.5–27.6] with nivolumab and 10.8 months [95% CI: 8.3–13.9] with placebo). The percentage of patients who were alive and disease-free at 6 months was 74.9% with nivolumab and 60.3% with placebo (HR for disease recurrence or death, 0.70; 98.22% CI: 0.55–0.90; p < 0.001). Among patients with a PD-L1 expression level of ≥ 1% (tumor cell [TC] score), the percentage of patients was 74.5% and 55.7%, respectively (HR: 0.55; 98.72% CI: 0.35–0.85; p < 0.001) [481]. In an analysis using both PD-L1 TC score and combined positive score (CPS), more patients had CPS ≥ 1 than TC ≥ 1% and patients with CPS ≥ 1 had improved DFS with nivolumab which may have contributed to the benefit seen with adjuvant nivolumab in patients with TC < 1% and CPS ≥ 1 [482]. There was no clinically meaningful deterioration in health-related quality of life with adjuvant nivolumab compared to placebo [483].

The primary endpoint of DFS was not achieved in a multi-centre RCT of adjuvant atezolizumab vs. observation in patients with ypT2–4a or ypN+ tumours following NAC or pT3–4a or pN+ tumours if no NAC was received (IMvigor010). Median DFS was 19.4 months (95% CI: 15.9–24.8) with atezolizumab and 16.6 months (11.2–24.8) with observation (stratified HR: 0.89, 95% CI: 0.74–1.08, p = 0.24) [484]. A similarly designed trial of pembrolizumab in the adjuvant setting has completed accrual with results awaited.

The FDA has approved nivolumab for adjuvant treatment of patients with UC who are at high risk of recurrence after undergoing surgery [485] whereas the EMA has approved adjuvant nivolumab for the treatment of adults with muscle-invasive UC (MIUC) with tumour cell PD-L1 expression ≥ 1%, who are at high risk of recurrence after undergoing radical resection of MIUC. A promising report (see Marker section) has suggested a potential role for ctDNA to guide the use of adjuvant IO for UC [486].

7.6.3. Summary of evidence and guidelines for adjuvant therapy

7.7. Metastatic disease

7.7.1. Introduction

The treatment of metastatic UC had remained largely unchanged since pivotal trials published over 20 years ago set the standard of care for first-line treatment with cisplatin-based combinations demonstrating an OS benefit. This longstanding paradigm was challenged in the past years by the introduction of immunotherapy using checkpoint inhibitors and it was finally upended in October 2023 with the presentation of the results of two practice-changing randomised clinical trials (RCTs) demonstrating an overall survival benefit in the first line setting against platinum-based chemotherapy (EV-302/KEYNOTE A39 and Checkmate 901) [487,488]. These updated guidelines reflect the results of these two trials and the impact for first and later lines management of patients with metastatic bladder cancer.

7.7.2. First-line systemic therapy for metastatic disease

In general, patients with untreated metastatic UC can be divided into two broad categories: eligible for combination therapies or ineligible for combination therapies. The distinction between the two groups is currently based on the eligibility criteria for the pivotal trial EV-302/KEYNOTE 39A and is likely to undergo changes in the near future based on results from real-world evidence investigations. Major criteria include ECOG performance status 0-2, GFR ≥ 30 ml/min and adequate organ functions based on eligibility for treatment with Enfortumab vedotin and Pembrolizumab. With regards to platinum-based chemotherapy the definitions to distinguish patients fit for cisplatin, fit for carboplatin und unfit for any platinum-based therapy remains valid as outlined below and summarised in Table 7.2.

7.7.2.1 Definitions: ‘Fit for cisplatin, fit for carboplatin, unfit for any platinum-based chemotherapy’

An international survey among BC experts [432] was the basis for a consensus statement on how to classify patients unfit for cisplatin-based chemotherapy. At least one of the following criteria must be present: PS > 1; GFR ≤ 60 mL/min; grade ≥ 2 audiometric hearing loss; grade ≥ 2 peripheral neuropathy or New York Heart Association (NYHA) class III heart failure [433]. Around 50% of patients with BC are not eligible for cisplatin-based chemotherapy [433]. Renal function assessment is of utmost importance for treatment selection. Measuring GFR with radioisotopes (⁹⁹mTc DTPA or ⁵¹Cr-EDTA) is recommended in equivocal cases.

Cisplatin has also been administered in patients with a lower GFR (40–60 mL/min) using different split-dose schedules. The respective studies were mostly small phase I and II trials in different settings (neoadjuvant and advanced disease) demonstrating that the use of split-dose cisplatin is feasible and appears to result in encouraging efficacy [486,489,490]. However, no prospective RCT has compared split-dose cisplatin with conventional dosing.

Most patients that are deemed unfit for cisplatin are able to receive carboplatin-based chemotherapy. However, some patients are deemed unfit for any platinum-based chemotherapy, i.e. both cisplatin and carboplatin. Patient are unfit for any platinum-based chemotherapy in case of PS > 2, GFR < 30 mL/min or the combination of PS 2 and GFR < 60 mL/min since the outcome in this patient population is poor regardless of platinum-based treatment or not [491]. Patients with multiple comorbidities may also be poor candidates for platinum-based chemotherapy.

Table 7.2: Definitions of platinum-eligibility for first-line treatment of metastatic urothelial carcinoma

ECOG = Eastern Cooperative Oncology Group; GFR = glomerular filtration rate; NYHA = New York HeartAssociation; PS = performance status.

7.7.2.1. First-line chemotherapy in patients fit for combination therapy

7.7.2.1.1. Enfortumab vedotin plus Pembrolizumab

The combination of Enfortumab vedotin (EV) plus pembrolizumab represents the new standard of care for patients who are deemed fit for combination therapies. This is based on EV-302/KEYNOTE 39A, a phase III trial that tested the antibody drug conjugate EV directed against nectin-4 (EV: administered any number of times until progression) in combination with the immune checkpoint inhibitor, pembrolizumab (maximum of 35 cycles) against platinum-based chemotherapy (cisplatin or carboplatin permitted) in combination with gemcitabine (up to 6 cycles) in the first-line advanced unresectable or metastatic urothelial carcinoma. 30% of the patients in the control arm received switch maintenance immunotherapy with avelumab. Both co-primary endpoints, PFS and OS were clearly met with a significant improvement in median PFS of 12.5 vs 6.3 months (HR 0.45 (0.38-0.54) and median OS of 31.5 vs. 16.1 months (HR 0.47 (0.38-0.58), respectively. The overall ORR was 67.7% including 29.1% complete remissions (CR) compared to 44.4% (12.5% CR) with platinum-based chemotherapy (p<0.00001). All pre-specified subgroups benefited equally from EV+pembrolizumab regardless of cisplatin eligibility, PD-L1 expression or presence of liver metastases. Treatment-related toxicity grade
≥ 3 was reported in 55% for EV/Pembrolizumab versus 70% in the chemotherapy arm. Specific and relevant EV toxicities include skin rash, peripheral neuropathy, ocular disorders and hyperglycemia. Toxicity of EV/Pembrolizumab needs to be managed proactively and attentively to avoid severe sequelae. The administration of EV/Pembrolizumab requires adequate knowledge and care from a specialised interprofessional team [487].

The combination of EV and pembrolizumab as the first-line treatment in 45 cisplatin-ineligible patients with locally-advanced/metastatic UC was also investigated in EV-103, phase 1b/2 study, and demonstrated a confirmed objective response rate after a median of nine cycles of 73.3% with a complete response rate of 15.6% [492]. The median duration of response and median OS were 25.6 months and 26.1 months, respectively. The most common treatment-related AEs were peripheral sensory neuropathy (55.6%), fatigue (51.1%), and alopecia (48.9%) [492]. A second cohort within the same study randomly assigned previously untreated cisplatin-ineligible patients to EV alone or EV with pembrolizumab [493]. The ORR was 64.5% (95% CI, 52.7 to 75.1) and 45.2% (95% CI, 33.5 to 57.3) for patients treated with EV+ pembrolizumab (N = 76) and EV monotherapy (N = 73), respectively. The median DOR was not reached for the combination and was 13.2 months for monotherapy. Based on these results enfortumab vedotin plus pembrolizumab has been granted FDA accelerated approval for patients with locally advanced or metastatic UC who are ineligible for cisplatin-containing chemotherapy.

7.7.2.1.2. Paitents eligible for combination therapy but not eligible for EV or EV not available

In spite of the very recent results of EV-302/KEYNOTE 39A study, EV will not be available in different countries. Moreover, some patients might not be eligible for or refuse treatment with EV including patients with uncontrolled diabetes, peripheral neuropathy grade ≥ 2 and pre-existing significant skin disorders. Platinum-based chemotherapy with integration of checkpoint inhibitors represents the preferred options in such patients. The general presumptions for cisplatin- and carboplatin-based therapy remain unchanged in this case and are outlined below.

7.7.2.1.2.1.Patients fit for cisplatin

Cisplatin-containing combination chemotherapy was the standard of care since the late 1980s demonstrating an OS of 12 to 14 months in different series (for a review see [494]). Methotrexate, vinblastine, adriamycin plus cisplatin and GC achieved survival of 14.8 and 13.8 months, respectively [495]. Overall response rates were 46% for MVAC and 49% for GC. The lower toxicity of GC [200] compared to standard MVAC has resulted in GC becoming the standard regimen.

Dose-dense MVAC combined with granulocyte colony-stimulating factor (G-CSF) is less toxic and more efficacious than standard MVAC in terms of, complete response (CR), and 2-year OS. However, there is no significant difference in median survival between the two regimens [496,497]. Further intensification of treatment using paclitaxel, cisplatin and gemcitabine (PCG) triplet regimen did not result in a significant improvement in OS in the intention-to-treat (ITT) population of a phase III RCT, comparing PCG to GC [498]. Similarly, the addition of the angiogenesis inhibitor bevacizumab to GC did not result in OS improvement [499].

The disease sites have an impact on long-term survival. In LN-only disease, 20.9% of patients were alive at five years compared to only 6.8% of patients with visceral metastases [495]. In the trials with long-term follow-up, approximately 10-15% of patients with metastatic UC were alive at 5 years and longer, suggesting a sustained benefit from cisplatin-based chemotherapy in a minority of patients [495,497].

Carboplatin-containing chemotherapy, without the inclusion of immunotherapy, is not considered to be equivalent to cisplatin-based combinations, and should not be considered interchangeable or standard in patients fit for cisplatin. A comparative analysis of four randomised phase II trials of carboplatin vs. cisplatin combination chemotherapy demonstrated lower CR rates and shorter OS for the carboplatin arms [500].
A retrospective study highlighted the importance of applying cisplatin in cisplatin-eligible patients in order to maintain benefit [501].

Switch maintenance with immunotherapy after platinum-based chemotherapy

A randomised phase II trial evaluated switch maintenance treatment with pembrolizumab in patients achieving at least stable disease on platinum-based first-line chemotherapy. The primary endpoint of PFS was met (5.4 months vs. 3.0 months, HR: 0.65, p = 0.04) [502].

The JAVELIN Bladder 100 study investigated the impact of switch maintenance with the PD-L1 inhibitor avelumab after initial treatment with platinum-gemcitabine chemotherapy. Patients achieving at least stable disease or better after 4–6 cycles of platinum-gemcitabine were randomised to avelumab or best supportive care (BSC). Overall survival was the primary endpoint which improved to 21.4 months with avelumab compared to 14.3 months with BSC (HR: 0.69, 95% CI: 0.56–0.86; p < 0.001). Of patients who discontinued BSC and received subsequent treatment 53% received immunotherapy. Immune-related AEs occurred in 29% of all patients and 7% experienced grade 3 complications [503]. Patient-reported ouctomes from JAVELIN Bladder 100 demonstrated no detrimental effect on quality of life [504].

Maintenance IO with avelumab was until recently standard of care for all patients with at least stable disease on first-line platinum-based chemotherapy.

If patients are fit for cisplatin, the results of CheckMate 901 should be considered [488]. This trial tested the addition of nivolumab in combination with gemcitabine/cisplatin (GC) and followed by nivolumab maintenance (until progression or maximum of 24 months) compared to GC alone. Of note, only 9% in the control arm received switch maintenance therapy with avelumab. The co-primary endpoints, PFS and OS were reached with a median PFS of 7.9 vs 7.6 months (HR 0.72, 95%CI 0.59-0.88) and a median OS of 21.7 vs. 18.9 months (HR 0.78, 95%CI 0.63-0.96). The response rate was improved with GC plus Nivolumab (57.6% vs 43.1.%). A complete remission (CR) was achieved in 21.7% of patients with Nivolumab plus GC with a duration of 37.1 months. Nivolumab plus GC had higher treatment related grade ≥3 toxicity (62% vs 52%). This combination represents an alternative to GC followed by maintenance therapy with avelumab in patients not eligible for EV or if EV is not available.

7.7.2.1.2.2.Patients fit for carboplatin (but unfit for cisplatin)

Up to 50% of patients are not fit for cisplatin-containing chemotherapy but most may be candidates for carboplatin [433]. A randomised phase II/III trial in this setting was conducted by the EORTC and compared two carboplatin-containing regimens (methotrexate/carboplatin/vinblastine [M-CAVI] and gemcitabine/carboplatin [GemCarbo]) in patients unfit for cisplatin. The EORTC definitions for eligibility were GFR < 60 mL/min and/or PS 2. Severe acute toxicity was 13.6% with GemCarbo vs. 23% with M-CAVI, while the ORR was 42% for GemCarbo and 30% for M-CAVI, respectively [491]. Based on these results the combination of carboplatin and gemcitabine should be considered a standard of care in this patient group. Importantly, both EV-302/KEYNOTE 39A and JAVELIN Bladder 100 included patients fit for carboplatin, while CheckMate 901 included patients fit for cisplatin only.

Combinations of gemcitabine and paclitaxel have been studied as first-line treatment and produced response rates between 38% and 60% but has never been tested in RCTs [505-507]. A randomised phase II trial assessed the efficacy and tolerability profile of two vinflunine-based regimens (vinflunine/gemcitabine vs. vinflunine/carboplatin). Both regimens showed equal ORR and OS with less haematologic toxicity for the combination of vinflunine/gemcitabine [508]. Non-platinum combination chemotherapy is nevertheless not recommended for first-line use in platinum-eligible patients.

The use of single-agent chemotherapy has been associated with varying response rates. Responses with single agents are usually short, complete responses are rare, and no long-term DFS/OS has been reported. It is not recommended for first-line treatment of metastatic UC.

7.7.2.2. First line therapy in patients not eligible for combination therapy

Limited data exist regarding the optimal treatment for this patient population which is characterised by severely impaired PS (PS > 2) and/or severely impaired renal function (GFR < 30 mL/min) or inadequate organ function. Historically, the outcome in this patient group has been poor. Best supportive care has often been chosen instead of systemic therapy. Most trials evaluating alternative treatment options to cisplatinum-based chemotherapy did not focus specifically on this patient population, making data interpretation difficult. The FDA (but not EMA) has approved pembrolizumab as a first-line treatment for patients not fit to receive any platinum-based chemotherapy regardless of PD-L1 status based on the results of one single-arm phase II trial [509].

Based on the results of two single arm phase II trials trials [509,510] the checkpoint inhibitors pembrolizumab and atezolizumab have been approved by EMA for first-line treatment in cisplatin- unfit patients in case of positive PD-L1 status. PD-L1 positivity for use of pembrolizumab is defined by immunohistochemistry as a CPS of ≥ 10 using the Dako 22C33 platform and for atezolizumab as positivity of ≥ 5% tumour-infiltrating immune cells using Ventana SP142.

Pembrolizumab was tested in 370 patients with advanced or metastatic UC ineligible for cisplatin, showing an ORR of 29% and CR in 7% of patients [509,511]. Atezolizumab was evaluated in the same patient population in a phase II trial (n = 119) showing an ORR of 23% with 9% of patients achieving CR [510].

First-line avelumab was evaluated in patients with PD-L1 positive, metastatic or locally advanced disease and demonstrated a median OS of 10.0 months (95% CI: 5.5-14.5 months) with 43% of patients alive at 1 year. A complete response was achieved in 8.5% of patients, and 15.5% had a partial response [512].

A phase 2 randomised trial (BAYOU) evaluating durvalumab with olaparib or placebo in platinum-ineligible patients with metastatic UC demonstrated no PFS or OS benefit for the addition of olaparib; however, in a secondary analysis of patients with homologous recombination repair gene mutations, PFS was improved with the addition of olaparib as compared to placebo (median PFS was 5.6 months (95% CI, 1.9 to 8.1) versus 1.8 months (95% CI, 1.7 to 2.2), (HR, 0.18; 95% CI, 0.06 to 0.47) [513].

The trials IMvigor 130, Keynote 361 and DANUBE all included an experimental arm with immunotherapy alone using atezolizumab, pembrolizumab and durvalumab, respectively [514-516]. No benefit in terms of PFS or OS for the use of single-agent immunotherapy compared to platinum-based chemotherapy was found. The combination of carboplatin/gemcitabine therefore is still considered the preferred first-line treatment choice for patients planned to receive chemotherapy who are ineligible for cisplatin.

7.7.2.3. Results of other trials integrating immunotherapy in the first line setting without OS benefit

In 2020, the results of three phase III trials were published investigating the use of immunotherapy in the first-line setting for platinum-eligible patients. The first trial to report was IMvigor130 investigating the combination of the PD-L1 inhibitor atezolizumab plus platinum-gemcitabine chemotherapy vs. chemotherapy plus placebo vs. atezolizumab alone [514]. The primary endpoint of PFS benefit for the combination vs. chemotherapy alone in the ITT group was reached (8.2 months vs. 6.3 months [HR: 0.82, 95% CI: 0.70–0.96; one-sided, p = 0.007]) while OS was not significant at the interim analysis after a median follow-up of 11.8 months. The small PFS benefit in the absence of an OS benefit has raised questions of its clinical significance.

The KEYNOTE 361 study had a very similar design using the PD-1 inhibitor pembrolizumab plus platinum-gemcitabine vs. chemotherapy plus placebo vs. pembrolizumab alone. The results of the primary endpoints of PFS and OS for the comparison of pembrolizumab plus chemotherapy vs. chemotherapy plus placebo in the ITT population showed no benefit for the combination [515].

DANUBE compared the immunotherapy combination (IO-IO) of CTLA-4 inhibitor tremelimumab and PD-L1 inhibitor durvalumab with chemotherapy alone or durvalumab alone [516]. The co-primary endpoint of improved OS for the IO-IO combination vs. chemotherapy was not reached in the ITT group nor was the OS improved for durvalumab monotherapy vs. chemotherapy in the PD-L1-positive population.

In conclusion, unlike CheckMate 901, these three trials do not support the use of combination of the PD-1/L1 checkpoint inhibitors plus platinum-based chemotherapy or the IO-IO combination as first-line treatment.

7.7.3. Further-line systemic therapy for metastatic disease

7.7.3.1. Introduction

Due to the results of the EV-302/KEYNOTE A39 trial and the expected paradigm shift in first-line therapy with establishment of the EV plus Pembrolizumab combination, as well as the CheckMate 901 trial with the combination of cisplatin, gemcitabine and nivolumab, selecting subsequent therapy lines in patients who fail during or progress after first-line treatment poses a significant challenge. Depending on the choice of first-line therapy the following options exist.

7.7.3.2. Chemotherapy

In patients eligible for combination therapy having received EV plus pembrolizumab, platinum-based chemotherapy with gemcitabine plus cisplatin or carboplatin may be considered, however, data is limited for this new post EV plus pembrolizumab clinical disease state and toxicities, e.g. neuropathy from prior therapy must be taken into consideration in determining a treatment plan. For patients already having received platinum-based chemotherapy with or without immunotherapy further -line chemotherapy data are highly variable and mainly derive from small single-arm phase II trials apart from one single phase III RCT. A reasonable strategy has been to re-challenge former platinum-sensitive patients if progression occurred at least six to twelve months after first-line platinum-based combination chemotherapy. A retrospective analysis of 296 patients within the RISC cohort (Retrospective International Study of Cancers of the Urothelium) revealed that subsequent platinum-based combination chemotherapy achieved a somewhat higher disease control rate (57.4% vs. 44.8%, p.= 0.041) and OS (7.9 vs. 5.5 months, p = 0.035) compared to subsequent non-platinum-based chemotherapy [517]. Second-line response rates of single-agent treatment with paclitaxel (weekly), docetaxel, gemcitabine, nab-paclitaxel, oxaliplatin, ifosfamide, topotecan, pemetrexed, lapatinib, gefitinib and bortezomib have ranged between 0% and 28% in small phase II trials [518,519].

The paclitaxel/gemcitabine combination has shown good response rates in small single-arm studies but no adequate phase III RCT has been conducted [520,521]. Vinflunine was tested in a phase III RCT and compared against BSC in patients progressing after first-line treatment with platinum-based chemotherapy [522]. The results showed a very modest ORR (8.6%), a clinical benefit with a favourable safety profile and a survival benefit, which was however only statistically significant in the eligible patient population (not in the ITT population). A randomised phase III trial evaluated the addition of the angiogenesis inhibitor ramucirumab to docetaxel chemotherapy vs. docetaxel alone, which resulted in improved PFS (4.1 vs. 2.8 months) and higher response rates (24.5% vs. 14%) but no OS benefit was achieved [523,524].

7.7.3.3. Immunotherapy for platinum-pre-treated patients without previous immunotherapy

The immune checkpoint inhibitors pembrolizumab, nivolumab, atezolizumab, avelumab, and durvalumab have demonstrated similar efficacy and safety in patients progressing during, or after, previous platinum-based chemotherapy in phase I, II and III trials.

Pembrolizumab demonstrated a significant OS Improvement as second-line treatment in a phase III RCT leading to EMA and FDA approval. Patients (n = 542) were randomised to receive either pembrolizumab monotherapy or chemotherapy (paclitaxel, docetaxel or vinflunine). The median OS with pembrolizumab was 10.3 months (95% CI: 8.0–11.8) vs. 7.4 months (95% CI: 6.1–8.3) with chemotherapy (HR 0.73, 95% CI: 0.59–0.91, p = 0.002) independent of PD-L1 expression levels [511,525].

Atezolizumab was the first checkpoint inhibitor approved by the FDA for metastatic UC based on the results of phase I and II trials [236,526], however, the indication has subsequently been withdrawn. The phase III RCT (IMvigor211) included 931 patients comparing atezolizumab with second-line chemotherapy (paclitaxel, docetaxel or vinflunine) did not meet its primary endpoint of improved OS for patients with high PD-L1 expression with 11.1 months (atezolizumab) vs. 10.6 (chemotherapy) months (stratified HR: 0.87, 95% CI: 0.63–1.21, p = 0.41) [470].

The PD-1 inhibitor nivolumab was approved by the FDA based on the results of a single-arm phase II trial (CheckMate 275), enrolling 270 platinum pre-treated patients. The primary endpoint of ORR was 19.6%, and OS was 8.74 months for the entire group [527]. The TITAN-TCC study evaluated the safety and activity of nivolumab induction plus high-dose ipilumumab (3 mg/kg) boosts in non-responders (stable or progressive disease) in the second-line treatment of 83 patients with metatsatic UC. Fifty (60%) received at least one boost with an investigator-assessed response rate of 33% (CR: 7%), demonstrating promising outcomes with this strategy compared to the rate reported in CheckMate 275 [528].

7.7.3.4. Side-effect profile of immunotherapy

Checkpoint inhibitors including PD-1 or PD-L1 antibodies and CTLA-4 antibodies have a distinct side-effect profile associated with their mechanism of action leading to enhanced immune system activity. These AEs can affect any organ in the body leading to mild, moderate or severe side effects. The most common organs affected are the skin, GI tract, liver, lung, thyroid, adrenal and pituitary gland. Other systems that may be affected include musculoskeletal, renal, nervous, haematologic, ocular and cardiovascular system. Any change during immunotherapy treatment should raise suspicion about a possible relation to the treatment. The nature of immune-related AEs has been very well characterised and published [529]. The timely and appropriate treatment of immune-related side effects is crucial to achieve optimal benefit from the treatment while maintaining safety. Clear guidelines for side-effect management have been published [530]. Immunotherapy treatment should be applied and supervised by trained clinicians only to ensure early side effect recognition and treatment. In case of interruption of immunotherapy, re-challenge will require close monitoring for AEs [531].

7.7.4. Integration of other agents

7.7.4.1. Antibody drug conjugates Enfortumab vedotin monotherapy

The first antibody drug conjugate to report encouraging data in patients previously treated with platinum-based chemotherapy and checkpoint inhibition was EV. The phase-II single-arm study EV-201 in 125 patients showed a confirmed objective response rate of 44%, including 12% complete responses [532]. This data led to accelerated FDA and EMA approval for EV in locally-advanced or metastatic UC patients who previously received a PD-1 or PD-L1 inhibitor and platinum-containing chemotherapy, as well as for cisplatin-ineligible patients who received one or more prior lines of therapy [533,534]. Another cohort of the same EV-201 trial demonstrated similar promising results in 91 patients that were cisplatin-ineligible and had received prior IO [535]. A phase III RCT (n = 608) comparing EV with single-agent chemotherapy after prior platinum chemotherapy and checkpoint inhibitor immunotherapy demonstrated significant survival benefit of almost 4 months (12.88 months vs. 8.97 months; HR 0.7, 95% CI: 0.56–0.89) [536]. The most common treatment-related AEs included alopecia (45%), peripheral neuropathy (34%), fatigue (31%, 7.4% ≥ grade 3), decreased appetite (31%), diarrhoea (24%), nausea (23%) and skin rash (16%, 7.4% ≥ grade 3).

7.7.4.2. Antibody drug conjugate Sacituzumab govetican

Another new and also promising antibody drug conjugate is sacituzumab govitecan, consisting of a humanised monoclonal antibody targeting trophoblast cell surface antigen 2 (Trop-2) conjugated to SN-38, the active metabolite of irinotecan. Sacituzumab govitecan was tested in 113 platinum and immunotherapy pre-treated metastatic UC (mUC) patients [532] and achieved an ORR of 27% and a total of 77% had a decrease in measurable disease, median PFS was 5.4 months and median OS 10.9 months [537]. Side effects consisted of haematological toxicities (neutropenia 34% ≥ grade 3; febrile neutropenia 10% ≥ grade 3), fatigue (52%), alopecia (47%), nausea (60%), diarrhea (65%, 10% ≥ grade 3) and decreased appetite (36%) [537]. Sacituzumab govitecan has received accelerated FDA approval for metastatic UC with prior platinum and IO pre-treatment. Several trials using sacituzumab govitecan as monotherapy or in combination are ongoing.

7.7.4.3. FGFR inhibition

Genomic profiling of UC has revealed common potentially actionable genomic alterations including alterations in FGFR [538]. Erdafitinib is a pan-FGFR tyrosine kinase inhibitor and the first FDA-approved targeted therapy for mUC with susceptible FGFR2/3 alterations following platinum-containing chemotherapy. The phase II trial of erdafitinib included 99 patients whose tumour harboured an FGFR3 mutation or FGFR2/3 fusion and who had disease progression following chemotherapy [234]. The confirmed ORR was 40% and an additional 39% of patients had stable disease. A total of 22 patients had previously received immunotherapy with only one patient achieving a response, yet the response rate for erdafitinib for this subgroup was 59%. At a median follow-up of 24 months, the median PFS was 5.5 months (95% CI: 4.0–6.0) and the median OS was 11.3 months (95% CI: 9.7–15.2) [234]. Treatment-related AEs of ≥ grade 3 occurred in 46% of patients. Common AEs of ≥ grade 3 were hyponatraemia (11%), stomatitis (10%), and asthenia (7%) and 13 patients discontinued erdafitinib due to AEs, including retinal pigment epithelial detachment, hand-foot syndrome, dry mouth, and skin/nail events. In a long-term follow up, the efficacy and safety profile remained similar with no new safety signals with longer follow-up [539].

In the recent THOR cohort 1 trial, a phase 3 trial of erdafitinib as compared with chemotherapy (docetaxel or vinflunine) in patients with metastatic UC with susceptible FGFR3/2 alterations who had progression after one or two previous treatments that included an anti–PD-1 or anti–PD-L1 demonstrated an improvement in OS with erdafitinib as compared to chemotherapy (12.1 months vs. 7.8 months; HR 0.64 (0.47 to 0.88); P=0.005). Median PFS was also longer with erdafitinib than with chemotherapy (5.6 vs. 2.7 months; (HR 0.58 (0.44 -0.78) [540]. Treatment-related toxicity grade ≥ 3 was similar in the two groups. The most common treatment-related adverse events of grade 3 or higher were palmar–plantar erythrodysesthesia syndrome (9.6%), stomatitis (8.1%), onycholysis (5.9%), and hyperphosphatemia (5.2%) in the erdafitinib group.

Data on cohort 2 with 351 patients, anti-PD-(l1) naïve and progressing after one prior treatment line compared Erdafitinib with pembrolizumab. No difference in the primary endpoint OS was detected (10.9 versus 11.1 months, HR 1.18 (0.92-1.51) [541]. Overall response rate was 40.0% and 21.6% and median duration of response was 4.3 and 14.4 months for erdafitinib and pembrolizumab, respectively. 64.7% and 50.9% of patients in the erdafitinib and pembrolizumab arms had ≥ 1 grade 3-4 adverse events.

In addition to erdafitinib, several other FGFR inhibitors are being evaluated including infigratinib which has demonstrated promising activity [235]. A phase 2/3 trial of the pan-FGFR inhibitor, rogaratinib versus chemotherapy in patients with locally advanced or metastatic UC with FGFR1-3 mRNA overexpression demonstrated similar outcomes as compared to chemotherapy [542]. The increased identification of FGFR3 mutations/fusion has led to several ongoing trials with different agents and combinations in different disease settings.

7.7.5. Current status of predictive biomarkers

The most important advance in recent years has been the recognition of alterations in FGFR3 including mutations and gene fusions as a predictive marker for response to FGFR inhibitors [234]. It is recommended to screen mUC patients ideally at diagnosis of metastatic disease for FGFR3 alterations to plan optimal treatment including trials.

Many efforts have focused on markers for predicting response to immune checkpoint inhibition. Programmed death-ligand 1 expression by immunohistochemistry has been evaluated in many studies with mixed and, so far, inconclusive results. This may in part be related to the use of different antibodies and various scoring systems evaluating different compartments i.e., tumour cells, immune cells, or both. A major limitation of PD-L1 staining relates to the significant proportion of PD-L1-negative patients that respond to immune checkpoint blockade. The predictive value of PD-L1 was not confirmed in large phase III trials evaluating the integration of immunotherapy in the first-line setting for mUC [514-516]. At present, the only indication for PD-L1 testing in mUC is dictated by current EMA approvals and relates to the potential use of immune checkpoint inhibitors as first-line monotherapy in patients unfit for cisplatin-containing chemotherapy.

Another biomarker that has been evaluated for predicting response to immunotherapy is high TMB [238]. Neoantigen burden and TMB have been associated with response to immune checkpoint blockade in several malignancies. High TMB has been associated with response to immune checkpoint inhibitors in metastatic UC in small single-arm trials [236,239] but was not confirmed so far in RCTs. Other markers that have been evaluated in predicting response to immune checkpoint inhibitors include molecular subtypes, CD8 expression by immunohistochemistry and other immune gene cell signatures. Recent work has focused on the importance of stroma including the role of TGFs in predicting response to immune checkpoint blockade [242,243].

In conclusion, apart from FGFR3 alterations, there are currently no further validated predictive molecular markers that are routinely used in clinical practice.

7.7.6. Special situations

7.7.6.1. Impact of prior neoadjuvant/adjuvant therapy on treatment sequence

Peri-operative systemic treatment is increasingly used in UC including cisplatin-based chemotherapy in the neoadjuvant setting for BC and adjuvant platinum-based chemotherapy for upper tract UC [543]. Many ongoing phase III trials investigate the use of immunotherapy in this setting as well (see Section 7.6.2). So far, one trial has reported a significant DFS benefit for adjuvant treatment with nivolumab compared with placebo whereas one trial reported no significant benefit using atezolizumab vs. placebo in the same setting whilst another trial reported negative findings [481,484]. It is expected that an increased number of patients with metastatic UC will have received pre-treatment with platinum and/or immunotherapy agents. No prospective trials have investigated the treatment of such patients. The choice of treatment in these patients depends on the applied peri-operative treatment and the time until relapse. If at least 12 months have passed since the end of peri-operative treatment the same systemic treatment as in treatment-naive patients is recommended.

7.7.6.2. Systemic treatment of metastatic disease with histology other than pure urothelial carcinoma

Pure UC represents the predominant histology in over 90% of patients with mUC. subtypes (e.g. micropapillary, nested, sarcomatoid) and divergent differentiation (e.g., SCC, adenocarcinoma) can be found in addition to pure UC in up to 33% of patients. Such patients were often excluded from large phase II and phase III trials and therefore the knowledge about the best management of such patients is limited. The respective literature was reviewed recently [66] and an expert Delphi survey and consensus conference provided guidance [82]. In case of predominant pure UC it is recommended to treat patients with mixed histology the same way as patients with a pure UC histology. Patients with predominant non-urothelial differentiation such as small cell neuroendocrine carcinoma, urachal adenocarcinoma, SCC and adenocarcinoma should be treated individually.

7.7.7. Treatment of patients with bone metastases

The prevalence of metastatic bone disease (MBD) in patients with advanced/metastatic UC is 30–40% [544]. Interestingly, a recent report described several observations related to age- and sex-related differences in the distribution of metastases in patients with metastatic BC and demonstrated that bone was the most common metastatic site in men with other differences noted according to patient age and sex [545]. Skeletal complications due to MBD have a detrimental effect on pain and QoL and are also associated with increased mortality [546]. Bisphosphonates such as zoledronic acid reduce and delay skeletal-related events (SREs) due to bone metastases by inhibiting bone resorption, as shown in a small pilot study [547]. Denosumab, a fully human monoclonal antibody that binds to and neutralises RANKL (receptor activator of nuclear factor κB ligand), was shown to be non-inferior to zoledronic acid in preventing or delaying SREs in patients with solid tumours and advanced MBD, including patients with UC [548]. Patients with MBD, irrespective of the cancer type, should be considered for bone-targeted treatment [546].

Patients treated with zoledronic acid or denosumab should be informed about possible side effects including osteonecrosis of the jaw and hypocalcaemia. Supplementation with calcium and vitamin D is mandatory. Dosing regimens of zoledronic acid should follow regulatory recommendations and have to be adjusted according to pre-existing medical conditions, especially renal function [549]. For denosumab, no dose adjustments are required for variations in renal function.

7.7.8. Summary: treatment algorithm for metastatic urothelial cancer update 2024

Figure 7.2 summarises the treatment algorithm for metastatic BC based on the evidence discussed in the text above. Patients with treatment-naive mUC can be divided into two broad categories: eligible for combination therapies or ineligible for combination therapies. The distinction between the two groups is currently based on the eligibility criteria for the pivotal trial EV-302/KEYNOTE 39A. Criteria include ECOG performance status 0-2, GFR ≥30ml/min and adequate organ functions with eligibility for treatment with EV and Pembrolizumab.

The combination of EV plus the checkpoint inhibitor pembrolizumab represents the new standard of care for patients who are deemed fit for combination therapies. In patients that might not be eligible for or refuse treatment with EV including patients with uncontrolled diabetes, peripheral neuropathy grade ≥2 and pre-existing significant skin disorders, platinum-based chemotherapy with integration of immune checkpoint inhibitors represents the preferred options.

With regards to platinum-based chemotherapy, the definitions are grouped according to platinum-eligibility based on clear definitions. In platinum-based chemotherapy, cisplatin is to be preferred to carboplatin. Patients who are cisplatin-ineligible but carboplatin-eligible should receive gemcitabine- carboplatin combination chemotherapy. In case of positive PD-L1 status, treatment with checkpoint inhibitors (atezolizumab or pembrolizumab) could be an alternative option.

Patients unfit for both cisplatin and carboplatin (platinum-unfit) can be considered for immunotherapy (FDA approved irrespective of PD-L1 status, EMA approved only for PD-L1 positive patients) or receive BSC.

In cases of disease stabilization or better on platinum-based chemotherapy switch, maintenance treatment with IO (avelumab) is recommended. Alternatively, patients can be followed closely and receive second-line immunotherapy at the time of progression (pembrolizumab).

It is recommended to determine FGFR mutation status before deciding about further-line treatment. Patients with FGFR3 mutations are candidates for FGFR inhibitor treatment.

Enfortumab vedotin therapy is standard in case of progression after platinum chemotherapy and IO, however based on EV-302/KEYNOTE 39A, the majority of patients will be candidates for EV plus pembrolizumab in the first-line setting. The optimal sequence of novel agents and potential combinations are the subject of many ongoing trials. It is generally recommended to treat patients within ongoing clinical trials whenever possible.

7.7.9. Summary of evidence and recommendations for metastatic disease

BSC = best supportive care; CPI = checkpoint inhibitor; EV = enfortumab vedotin; GC = gemcitabine plus cisplatin; FGFR = fibroblast growth factor receptor

Figure 7.2: Flow chart for the management of metastatic urothelial cancer**EV = enfortumab vedotin; FGFR = fibroblast growth factor receptor; GFR = glomerular filtration rate; PS = performance status; CPI=checkpoint inhibitor; PD-L1= programmed deathligand 1; PD= programmed death

7.8. Quality of life

7.8.1. Introduction

The evaluation of HRQoL considers physical, psychological, emotional and social functioning. In patients with MIBC, HRQoL is affected, particularly in the physical and social functioning domains [550,551].

Several questionnaires have been validated for assessing HRQoL in patients with BC, including FACT-G [552], EORTC QLQ-C30/BLM30 [553], SF-36 [554] and the Bladder Cancer Index (BCI) [555]. In spite of these validated questionnaires, there is heterogeneity in the measurements used to assess sexual health. A health questionnaire that covers the entire range of sexual health in bladder cancer patients is currently lacking [556].

Regardless of the which questionnaire is used, assessment of the baseline and post-treatment HRQoL is important. Questionnaires are helpful tools in clinical decision making, but, in addition, data support the prognostic value of baseline HRQoL [557]. In a large population-based study of patients with MIBC and no prior psychiatric history, 31% of all patients with MIBC were diagnosed with a new mental health disorder after their bladder cancer diagnosis [558].

7.8.2. Neoadjuvant chemotherapy

Two RCTs including patiens undergoing NAC have published their HRQoL data [459,559]. Huddart et al., analysed the subset of patients within the BC2001 trial who underwent NAC prior to (chemo)radiation. Using the FACT-BL questionnaire, no detrimental impact of NAC on HRQoL was observed [459]. Kitamura et al., reported on 64 patients included in the JCOG0209 study who underwent NAC (MVAC vs. MVAC and RC). An overall decline on HRQoL was reported directly following NAC using the FACT-BL questionnaire. However, no difference in HRQoL was observed after the consolidating RC.

7.8.3. Radical cystectomy and urinary diversion

Two systematic reviews and meta-analyses focused on HRQoL after RC and urinary diversion [366,560].

Yang et al., compared HRQoL of incontinent and continent urinary diversions (all types) including 29 studies (n = 3,754) of which 9 had a prospective design (one of which was randomised) [366]. Only three studies reported HRQoL data both pre- and post-operatively. All these three studies reported an initial deterioration in overall HRQoL but general health, functional and emotional domains at 12 months post-surgery were equal or better than baseline. Overall, no difference in HRQoL between continent and incontinent urinary diversion was reported although an ileal conduit may confer a small physical health benefit [560].

Cerruto et al., reported HRQoL comparing ileal conduit with orthotopic neobladder reconstruction [560]. A pooled analysis was performed including 18 studies (n = 1,553) of which the vast majority were retrospective studies. Although this study was hampered by methodological limitations, no statistical significant difference in overall HRQoL was found.

Altogether, there appears to be no superior type of urinary diversion in terms of overall HRQoL but it is rather a result of proper patient selection. An older and isolated patient is probably better served with an ileal conduit, whereas a younger patient with a higher level of interest in body image and sexuality is better off with an orthotopic diversion. The patient’s choice is the key to the selection of reconstruction method [366].

A number of RCTs comparing ORC with RARC (with either intra- or extracorporeal urinary diversion) have reported their HRQoL data [358,561-563]. All studies reported no statistical significant difference in HRQoL outcomes between surgical techniques.

7.8.4. Adjuvant therapy

HRQoL data was reported in the phase 3 Checkmate 274 RCT where patients were randomised for adjuvant nivolumab or placebo after radical surgery for bladder cancer or UTUC. Patients were not pre-treated with NAC. No clinically meaningful detoration in HRQoL was observed during nivolumab treatment (based on the EORTC QLQ-C30/VAS questionnaire) [483].

7.8.5. Bladder-sparing trimodality therapy

The only HRQoL data in bladder sparing treatment collected in a RCT setting was published by Huddart et al. [459]. The primary endpoint was the change in the Bladder Cancer Subscale (BLCS), as part of the FACT-BL questionnaire, at one year post-treatment. Questionnaire return rate at one and five years was 70% and 60%, respectively. A reduction in HRQoL was seen in the majority of the domains immediately following RT, however, in most patients the HRQoL scores returned to baseline 6 months after RT and maintained at this level for five years. Approximately 33% of patients reported persistent lower Bladder Cancer Subscale scores after five years. Addition of chemotherapy did not affect the HRQoL outcomes. Also see section 7.5.4 for further discussion of QoL after TMT.

7.8.6. Non-curative or metastatic bladder cancer

In patients with primary non-curative or metastastic disease HRQoL is reduced because of associated micturition problems, bleeding, pain and therefore disturbance of social and sexual life [564]. Beneficial impact of palliative surgery [565], RT [566], and/or chemotherapy on bladder-related symptoms have been described [567].

A HRQoL analysis was performed in platinum-refractory patients who were randomised to pembrolizumab vs. another line of chemotherapy (KEYNOTE-45 trial) [568]. It was reported that patients treated with pembrolizumab had stable or improved global health status/QoL, whereas those treated with investigators’ choice of chemotherapy experienced declines in global health [568].

Recently, HRQoL data was presented from cohort 1 of the EV-201 study including 125 patients treated with enfortumab vedotin after failing previous treatment with platinum chemotherapy and anti–PD-1/L1 therapy [569]. Patients who remained on enfortumab vedotin treatment showed no detoriation in HRQoL. In patients with bone metastases at baseline, pain control and possibly pain reduction was observed.

7.8.7. Summary of evidence and recommendations for health-related quality of life